<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">53550</article-id><article-id pub-id-type="doi">10.7554/eLife.53550</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>ARID1A loss in adult hepatocytes activates β-catenin-mediated erythropoietin transcription</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-165886"><name><surname>Riou</surname><given-names>Rozenn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165887"><name><surname>Ladli</surname><given-names>Meriem</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165888"><name><surname>Gerbal-Chaloin</surname><given-names>Sabine</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165889"><name><surname>Bossard</surname><given-names>Pascale</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165890"><name><surname>Gougelet</surname><given-names>Angélique</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165891"><name><surname>Godard</surname><given-names>Cécile</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198170"><name><surname>Loesch</surname><given-names>Robin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165892"><name><surname>Lagoutte</surname><given-names>Isabelle</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165893"><name><surname>Lager</surname><given-names>Franck</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165894"><name><surname>Calderaro</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198171"><name><surname>Dos Santos</surname><given-names>Alexandre</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165895"><name><surname>Wang</surname><given-names>Zhong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8720-4609</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165896"><name><surname>Verdier</surname><given-names>Frédérique</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-135446"><name><surname>Colnot</surname><given-names>Sabine</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3949-9107</contrib-id><email>sabine.colnot@inserm.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers (CRC)</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution>Equipe labellisée Ligue Nationale Contre le Cancer</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution>INSERM, CNRS, Institut COCHIN</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff4"><label>4</label><institution>INSERM U1183, Université Montpellier, Institute for Regenerative Medicine &amp; Biotherapy (IRMB)</institution><addr-line><named-content content-type="city">Montpellier</named-content></addr-line><country>France</country></aff><aff id="aff5"><label>5</label><institution>Plateforme d’Imageries du Vivant de l’Université de Paris</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff6"><label>6</label><institution>INSERM, Université Paris-Est UPEC</institution><addr-line><named-content content-type="city">Créteil</named-content></addr-line><country>France</country></aff><aff id="aff7"><label>7</label><institution>Department of Pathology, Henri Mondor Hospital</institution><addr-line><named-content content-type="city">Créteil</named-content></addr-line><country>France</country></aff><aff id="aff8"><label>8</label><institution>INSERM, Paul-Brousse University Hospital, Hepatobiliary Centre</institution><addr-line><named-content content-type="city">Villejuif</named-content></addr-line><country>France</country></aff><aff id="aff9"><label>9</label><institution>Department of Cardiac Surgery Cardiovascular Research Center, University of Michigan</institution><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><role>Senior Editor</role><aff><institution>Max Planck Institute for Heart and Lung Research</institution><country>Germany</country></aff></contrib><contrib contrib-type="editor"><name><surname>Davidson</surname><given-names>Irwin</given-names></name><role>Reviewing Editor</role><aff><institution>Institut de Génétique et de Biologie Moléculaire et Cellulaire</institution><country>France</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>21</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e53550</elocation-id><history><date date-type="received" iso-8601-date="2019-11-12"><day>12</day><month>11</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-10-20"><day>20</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Riou et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Riou et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-53550-v2.pdf"/><abstract><p>Erythropoietin (EPO) is a key regulator of erythropoiesis. The embryonic liver is the main site of erythropoietin synthesis, after which the kidney takes over. The adult liver retains the ability to express EPO, and we discovered here new players of this transcription, distinct from the classical hypoxia-inducible factor pathway. In mice, genetically invalidated in hepatocytes for the chromatin remodeler <italic>Arid1a</italic>, and for <italic>Apc</italic>, the major silencer of Wnt pathway, chromatin was more accessible and histone marks turned into active ones at the <italic>Epo</italic> downstream enhancer. Activating β-catenin signaling increased binding of Tcf4/β-catenin complex and upregulated its enhancer function. The loss of <italic>Arid1a</italic> together with β-catenin signaling, resulted in cell-autonomous <italic>EPO</italic> transcription in mouse and human hepatocytes. In mice with <italic>Apc-Arid1a</italic> gene invalidations in single hepatocytes, Epo de novo synthesis led to its secretion, to splenic erythropoiesis and to dramatic erythrocytosis. Thus, we identified new hepatic <italic>EPO</italic> regulation mechanism stimulating erythropoiesis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>chromatin remodeling</kwd><kwd>Wnt signaling</kwd><kwd>epo transcription</kwd><kwd>liver physiopathology</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006364</institution-id><institution>Institut National Du Cancer</institution></institution-wrap></funding-source><award-id>Epigenetics and Liver Cancer</award-id><principal-award-recipient><name><surname>Riou</surname><given-names>Rozenn</given-names></name><name><surname>Gougelet</surname><given-names>Angélique</given-names></name><name><surname>Godard</surname><given-names>Cécile</given-names></name><name><surname>Calderaro</surname><given-names>Julien</given-names></name><name><surname>Colnot</surname><given-names>Sabine</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004099</institution-id><institution>Ligue Contre le Cancer</institution></institution-wrap></funding-source><award-id>Equipe Labellisée</award-id><principal-award-recipient><name><surname>Riou</surname><given-names>Rozenn</given-names></name><name><surname>Gougelet</surname><given-names>Angélique</given-names></name><name><surname>Godard</surname><given-names>Cécile</given-names></name><name><surname>Colnot</surname><given-names>Sabine</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>Labex &quot;Who Am I&quot;</award-id><principal-award-recipient><name><surname>Riou</surname><given-names>Rozenn</given-names></name><name><surname>Gougelet</surname><given-names>Angélique</given-names></name><name><surname>Godard</surname><given-names>Cécile</given-names></name><name><surname>Colnot</surname><given-names>Sabine</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006364</institution-id><institution>Institut National Du Cancer</institution></institution-wrap></funding-source><award-id>Chromaliv</award-id><principal-award-recipient><name><surname>Riou</surname><given-names>Rozenn</given-names></name><name><surname>Gougelet</surname><given-names>Angélique</given-names></name><name><surname>Godard</surname><given-names>Cécile</given-names></name><name><surname>Colnot</surname><given-names>Sabine</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>Idex &quot;EpilivCan&quot;</award-id><principal-award-recipient><name><surname>Riou</surname><given-names>Rozenn</given-names></name><name><surname>Gougelet</surname><given-names>Angélique</given-names></name><name><surname>Godard</surname><given-names>Cécile</given-names></name><name><surname>Colnot</surname><given-names>Sabine</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A chromatin remodeling factor cooperates with Wnt signaling pathway to transcribe erythropoietin in the adult liver, inducing its secretion and a dramatic erythropoiesis in the spleen.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Chromatin dynamics strongly modulates gene expression, and the liver is a prominent tissue in which chromatin opening is a pre-pattern for cell fate programming (<xref ref-type="bibr" rid="bib64">Zaret, 2016</xref>). ARID1A, ‘AT-rich interacting domain containing protein 1A’, is a BAF (BRG1-associated factors) subunit of the highly evolutionarily conserved SWI/SNF chromatin remodeling complexes. These complexes use the energy of ATP hydroxylation to reposition, eject, or exchange nucleosomes and thus modulate DNA accessibility (<xref ref-type="bibr" rid="bib15">de la Serna et al., 2006</xref>). They are essential for the regulation of gene expression and are involved in several cellular functions, such as differentiation, development, proliferation, DNA repair, and adaptation to the extracellular environment (<xref ref-type="bibr" rid="bib26">Kadoch et al., 2016</xref>). Recently, mutations in chromatin modifying factors have been identified in several types of cancer (<xref ref-type="bibr" rid="bib26">Kadoch et al., 2016</xref>).</p><p>In the adult mouse liver, Arid1a has been shown to play a role in liver regeneration and in tumorigenesis (<xref ref-type="bibr" rid="bib51">Sun et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Sun et al., 2016</xref>). In human hepatocellular carcinoma (HCC), the most common primary liver cancer (<xref ref-type="bibr" rid="bib57">Torre et al., 2016</xref>), <italic>ARID1A</italic> is the chromatin modifier gene the most frequently inactivated (&gt;13% of HCCs). These mutations are preferentially found in HCC with activating mutations of the <italic>CTNNB1</italic> gene encoding β-catenin, accounting for one third of HCC (<xref ref-type="bibr" rid="bib21">Guichard et al., 2012</xref>; <xref ref-type="bibr" rid="bib43">Rebouissou et al., 2016</xref>). This suggested a potential link between Wnt/β-catenin pathway and ARID1A for the regulation of hepato-specific gene expression programs involved in liver pathophysiology.</p><p>In the adult liver, the Wnt/β-catenin pathway can induce both physiological and oncogenic effects (<xref ref-type="bibr" rid="bib10">Cavard et al., 2008</xref>; <xref ref-type="bibr" rid="bib12">Colnot, 2016</xref>; <xref ref-type="bibr" rid="bib37">Monga, 2015</xref>). Such signaling is restricted to the hepatocytes surrounding the central vein, the so-called pericentral hepatocytes, where it is activated by nearby endothelial Wnt and R-Spondin ligands (<xref ref-type="bibr" rid="bib42">Planas-Paz et al., 2016</xref>; <xref ref-type="bibr" rid="bib5">Benhamouche et al., 2006</xref>). β-catenin transcriptionnally patterns the liver to ensure its pericentral metabolic functions (<xref ref-type="bibr" rid="bib18">Gougelet et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Torre et al., 2011</xref>). A genetically engineered panlobular activation of the Wnt/β-catenin pathway quickly induced a pericentral-like liver phenotype and hepatomegaly, resulting in mouse death (<xref ref-type="bibr" rid="bib5">Benhamouche et al., 2006</xref>). Additionally, the focal activation of β-catenin in vivo in single murine hepatocytes is oncogenic, leading to the development of β-catenin-activated liver tumors (<xref ref-type="bibr" rid="bib11">Colnot et al., 2004</xref>). We used transcriptomic and metabolomic approaches and showed that the genetic program expressed in β-catenin-activated liver is similar to the oncogenic signature found in human HCC harboring activating β-catenin mutations (<xref ref-type="bibr" rid="bib18">Gougelet et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Gougelet et al., 2019</xref>; <xref ref-type="bibr" rid="bib47">Senni et al., 2019</xref>).</p><p>When activated, β-catenin translocates into the nucleus and interacts with its co-factor Tcf4 to bind Wnt-responsive elements (WRE) located in the vicinity of target genes (<xref ref-type="bibr" rid="bib18">Gougelet et al., 2014</xref>). Chromatin remodeling processes have been shown to unlock chromatin over WREs, allowing β-catenin to dictate specific transcriptomic programs (<xref ref-type="bibr" rid="bib38">Mosimann et al., 2009</xref>). Given the frequent inactivation of <italic>ARID1A</italic> in <italic>CTNNB1</italic>-mutated liver tumors, our aim was to determine in mice whether and how the loss of the chromatin remodeler Arid1a cooperates with β-catenin to impact on mouse liver pathophysiology. We used transgenic murine models in which the main brake of the Wnt/β-catenin pathway, the tumor suppressor <italic>Adenomatous polyposis coli</italic> (<italic>Apc)</italic> (<xref ref-type="bibr" rid="bib11">Colnot et al., 2004</xref>) and/or <italic>Arid1a</italic> (<xref ref-type="bibr" rid="bib17">Gao et al., 2008</xref>) are lost in adult hepatocytes. We unexpectedly revealed a novel major function of ARID1A and the Wnt/β-catenin pathway in regulating <italic>EPO</italic> expression and adult erythropoiesis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Emergence of peliosis-like regions in the liver of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice</title><p>We investigated the effects of the loss of the chromatin remodeler Arid1a in a context of focal and aberrant β-catenin activation. To do so, we injected transgenic mice carrying <italic>Apc</italic> and/or <italic>Arid1a</italic> floxed genes with a low dose of Cre-expressing Adenovirus (AdCre) known to mainly target the liver (<xref ref-type="bibr" rid="bib11">Colnot et al., 2004</xref>). In <italic>Apc-</italic>floxed mice, we previously showed that this dose was sufficient to induce β-catenin activation in single hepatocytes and promote tumorigenesis without killing the mice (<xref ref-type="bibr" rid="bib11">Colnot et al., 2004</xref>). Accordingly, this injection in compound <italic>Apc/Arid1a</italic>-floxed mice inactivated both <italic>Apc</italic> and <italic>Arid1a</italic> genes in approximately 20% of hepatocytes ([<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice, <xref ref-type="fig" rid="fig1">Figure 1a</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Development of peliosis-like regions after hepato-specific and focal <italic>Arid1a</italic> and <italic>Apc</italic> inactivation.</title><p>(<bold>a</bold>) Cre-loxP-generated hepatocyte-specific and inducible inactivation of <italic>Apc</italic> and/or <italic>Arid1a</italic> in 20% of hepatocytes after retro-orbital injection of infectious viral particles (ivp) of adenovirus encoding Cre recombinase (AdCre). The resulting mice are referred to as [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup>, [<italic>Apc</italic>]<sup>ko-focal</sup>, and [<italic>Arid1a</italic>]<sup>ko-focal</sup>. (<bold>b</bold>) Gross examination of mouse livers, 7 months after AdCre injection. Livers from [<italic>Apc-Arid1a</italic>]<italic><sup>ko-focal</sup></italic> mice had an irregular shape and a rough surface, with multiple dark red zones (indicated by arrows). (<bold>c</bold>) Incidence of hepatic lesions detected in WT (n = 10) and [<italic>Apc-Arid1a</italic>]<italic><sup>ko-focal</sup></italic> (n = 24) mice by ultrasonography. (<bold>d</bold>) Kaplan-Meier estimated survival curves of WT and [<italic>Apc-Arid1a</italic>]<italic><sup>ko-focal</sup></italic> mice over 15 months. n = 6 for each group. Inset: Liver of one mouse at necropsy (13 months after AdCre injection, representative of the three analyzed mice). (<bold>e</bold>) Hematoxylin Eosin (HE)-stained sections of mouse livers at 7 months post-injection. Large vascular spaces filled with blood cells were observed only in [<italic>Apc-Arid1a</italic>]<italic><sup>ko-focal</sup></italic> livers. Related data are found in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1</xref>–<xref ref-type="fig" rid="fig1s4">4</xref>, and source data in ‘<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>; <xref ref-type="supplementary-material" rid="fig1s1sdata1">Figure 1—figure supplement 1—source data 1</xref>; <xref ref-type="supplementary-material" rid="fig1s3sdata1">Figure 1—figure supplement 3—source data 1</xref>’.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Emergence of peliosis (<xref ref-type="fig" rid="fig1">Figure 1c</xref>) and survival curve (<xref ref-type="fig" rid="fig1">Figure 1d</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Focal inactivation of <italic>Apc</italic> and/or <italic>Arid1a</italic> genes in mouse liver.</title><p>(<bold>a</bold>) Liver to Body weight (%) in mice; WT (n = 8), [<italic>Apc</italic>]<sup>ko-focal</sup> (n = 10), [<italic>Arid1a</italic>]<sup>ko-focal</sup> (n = 18), and [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> (n = 19) mice. (<bold>b</bold>) RT-qPCR analysis of β-catenin-positive target genes from seven-month-old-mouse livers. WT (n = 5), [<italic>Apc</italic>]<sup>ko-TOTAL</sup> (n = 7), [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 12), and [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 10) mice. The data in (<bold>a,b</bold>) are expressed as the mean ± SEM and analyzed with one-way ANOVA. (<bold>c,d</bold>) Immunostainings against glutamine synthetase (Glul) and Arid1a after focal <italic>Apc</italic> and/or <italic>Arid1a</italic> loss. (<bold>c</bold>) Note the physiological staining of Glul in hepatocytes surrounding the centrolobular vein (cv). Focal activation of β-catenin signaling in single hepatocytes leads to an immunostaining of Glul, its hepatospecific target (red asterisk). Scale bars = 200 μm. (<bold>d</bold>) Immunofluorescence for Glul in hepatocytes without Arid1a nuclear fluorescence (white asterisk), shows the efficiency and specificity of the double <italic>Apc</italic>/<italic>Arid1a</italic> inactivation in [<italic>Apc-Arid1a</italic>]<sup>ko-focal livers</sup> (white asterisk). Scale bars = 100 μm.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Liver to body weight ratios (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1a</xref>) and expression of Glul and Axin2 mRNAs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1b</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Ultrasound features of livers from seven-month-old [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice.</title><p>(<bold>a</bold>) Echogenicity of peliotic areas within the [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> liver (arrow), showing striking tissue modification. Scale bars = 2 cm. (<bold>b</bold>) Dynamic contrast-enhanced ultrasound using microbubble administration. Contrast-enhanced ultrasound imaging involves the injection of gas-filled micron-sized bubbles (microbubbles) that do not extravasate. This property makes them ideal contrast agents for imaging vascularity and blood perfusion. The protocol has been described in <xref ref-type="bibr" rid="bib48">Snipstad et al., 2017</xref>. It revealed a decrease of hepatic vascular perfusion within echogenic areas compared to neighboring control tissue.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Blood vessel enrichment and angiogenesis in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> livers.</title><p>(<bold>a</bold>) Peliotic areas appeared as abnormal tangles of irregularly shaped, leaky, small and large blood vessels filled with red blood cells, with multiple, mottled cyst-like spaces associated with sinusoidal dilatation and liver cell dropout in the livers of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice (1), relative to neighboring tissue (2). Scale bars = 200 μm (left panel) and 100 μm (right panel). (<bold>b</bold>) Immunofluorescence, at different magnifications, against β-catenin and Pecam1 of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> liver. Peliosis-like area, showing strong enrichment of blood vessels (1) compared to neighboring tissue (2). (<bold>c</bold>) RT-qPCR analysis of angiogenic factors from 7-month-old-mouse livers. WT (n = 5), [<italic>Apc</italic>]<sup>ko-TOTAL</sup> (n = 7), [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 12), and [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 10) mice. Data are presented as the mean + SEM and analyzed by one-way ANOVA.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>qPCR expression of angiogenic mRNAs (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplements 3c</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig1-figsupp3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Hepatocarcinogenesis in β-catenin-activated and Arid1a-null context.</title><p>(<bold>a–c</bold>) HCC incidence decrease in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> compared to [<italic>Apc</italic>]<sup>ko-focal</sup> mice. (<bold>a</bold>) Incidence of HCC was detected by ultrasound in [<italic>Apc</italic>]<italic><sup>ko-focal</sup></italic> (n = 13) and [<italic>Apc-Arid1a</italic>]<italic><sup>ko-focal</sup></italic> (n = 24) mice. (<bold>b</bold>) Two representative livers of ten-month-old [<italic>Apc</italic>]<italic><sup>ko-focal</sup></italic> and [<italic>Apc-Arid1a</italic>]<italic><sup>ko-focal</sup></italic> mouse livers presenting tumor. (<bold>c</bold>) Immunostaining of glutamine synthetase (Glul) and Arid1a in [<italic>Apc</italic>]<italic><sup>ko-focal</sup></italic> and [<italic>Apc-Arid1a</italic>]<italic><sup>ko-focal</sup></italic> liver sections. NT: non tumoral tissue; Tum: tumor; Scale bars = 200 μm. (<bold>d</bold>) EPO expression in human HCC depending on their <italic>CTNNB1</italic> and <italic>ARID1A</italic> mutational status. Datasets in hepatocellular carcinoma were downloaded from the Cancer Genome Atlas (TCGA) data portal (<ext-link ext-link-type="uri" xlink:href="http://tcga-data.nci.nih.gov">http://tcga-data.nci.nih.gov</ext-link>). We extracted two types of molecular data including gene expression and somatic mutation using TCGA2STAT R package. Fours groups of tumors were clusterized based on mutation status: <italic>CTNNB1</italic>-mutated (n = 46), <italic>ARID1A</italic>-mutated (n = 11), <italic>CTNNB1/ARID1A-</italic>mutated (n = 5) and no <italic>CTNNB1</italic> nor <italic>ARID1A</italic> mutations (n = 133). Analysis of variance and post-hoc tests were performed to test the association between EPO expression and mutation status.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig1-figsupp4-v2.tif"/></fig></fig-group><p>Surprisingly, an ultrasound follow-up showed the development of striking echogenic features in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mouse livers from 5 months after AdCre injection (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplements 2a</xref>). We revealed after dissection that these livers harbored numerous and irregular dark red to black vascular lesions (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). After 10 months, all [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice (n = 24) exhibited blood-filled lacunar spaces (<xref ref-type="fig" rid="fig1">Figure 1c</xref>), as well as hepatomegaly (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1a</xref>). We did not however observe such phenotypic abnormalities in the [<italic>Apc</italic>]<sup>ko-focal</sup> (n = 13), 18 [<italic>Arid1a</italic>]<sup>ko-focal</sup> (n = 18), or control (n = 10) mice studied. [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice exhibited 50% and 100% mortality at 10 and 14 months, respectively (<xref ref-type="fig" rid="fig1">Figure 1d</xref>). In dying mice, we discovered that the whole liver was diseased and dark red in color. Indeed, the liver was filled with blood, harboring large necrotic areas with no remaining healthy zones (<xref ref-type="fig" rid="fig1">Figure 1d</xref>, inset).</p><p>Histologically, the diseased [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> liver showed abnormal blood vessels that were partially or completely full of red blood cells (RBCs) (<xref ref-type="fig" rid="fig1">Figure 1e</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplements 3a</xref>), associated with sinusoidal dilatation and liver cell dropout. Additionally, using microbubble-assisted ultrasound, we showed a decrease in hepatic vascular perfusion within echogenic areas, illustrating hence a vascular liver disease (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplements 2a</xref>). We thus characterized these areas with dramatic histological features as peliosis-like areas, similar to the human vascular disease, peliosis.</p><p>In accordance with previous results (<xref ref-type="bibr" rid="bib11">Colnot et al., 2004</xref>), β-catenin-activated liver tumors developed in 92% of [<italic>Apc</italic>]<sup>ko-focal</sup> mice (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplements 4a</xref>). Here, only 8% of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice developed liver tumors which were both β-catenin-activated and <italic>Arid1a</italic>-invalidated (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplements 4a-c</xref>), suggesting that Arid1a loss suppresses the tumorigenic effect of activated Wnt/β-catenin signaling in the liver. However, this model was not appropriate for assessing the effects of <italic>Arid1a</italic> loss on Wnt/β-catenin-dependent hepatocarcinogenesis in these mice, given the emergence of peliosis and lethality at a stage preceding or overlapping the expected tumor initiation phase (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplements 4a-c</xref>).</p><p>We reveal here that β-catenin activation and Arid1a loss cooperate to induce a dramatic hepatic peliosis and lethality in the mouse.</p></sec><sec id="s2-2"><title>Hepatic loss of both <italic>Arid1a</italic> and <italic>Apc</italic> results in erythrocytosis linked to de novo transcription of <italic>Epo</italic></title><p>We performed transcriptomic microarray analysis of micro-dissected [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> livers (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). Firstly, gene set enrichment analysis (GSEA) revealed transcriptional signatures linked to angiogenesis and the Erythropoietin (EPO) pathway in peliosis-like areas relative to adjacent regions (<xref ref-type="fig" rid="fig2">Figure 2b,c</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref>). Additionally, these peliosis-like regions showed a Wnt/β-catenin transcriptional signature, revealing enrichment of β-catenin-activated cells within these areas.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Hepatic peliosis has ‘angiogenic’ and ‘erythropoietin’ transcriptional signatures, linked to a systemic erythrocytosis and to de novo hepatic <italic>Epo</italic> expression in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice.</title><p>(<bold>a</bold>) Experimental strategy; (<bold>b</bold>) Transcriptomic gene-set enrichment analysis (GSEA) of hepatic peliosis (n = 4) relative to adjacent regions (n = 4) of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice. (<bold>c</bold>) Quantitative RT-PCR showing relative expression of mRNAs for positive targets of hepatic Wnt/β-catenin pathway and angiogenic factors in hepatic peliosis (n = 10) compared to adjacent regions (n = 10) of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice (unpaired t test analysis); (<bold>d</bold>) Hematological parameters from WT (n = 7), [<italic>Apc</italic>]<sup>ko-focal</sup> (n = 12), [<italic>Arid1a</italic>]<sup>ko-focal</sup> (n = 19), and [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> (n = 20) mice (One-way ANOVA analysis). (<bold>e</bold>) Evaluation of erythropoietin (<italic>Epo</italic>) mRNAs by quantitative RT-PCR in the livers analyzed by the ΔCt technique and expressed relative to those for 18S RNA for the liver, and as relative levels in the kidney (One-way ANOVA analysis). (<bold>f</bold>) Plasma EPO concentrations at sacrifice (WT (n = 6), [<italic>Apc</italic>]<sup>ko-focal</sup> (n = 5), [<italic>Arid1a</italic>]<sup>ko-focal</sup> (n = 2), and [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> (n = 10)). Exact p-values are mentioned, ****p&lt;0.0001. Related data are found in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref> and source data in ‘<xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>'.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Gene expression (<xref ref-type="fig" rid="fig2">Figure 2c, e</xref>) and hematological parameters (<xref ref-type="fig" rid="fig2">Figure 2d</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Peliosis-like regions from [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> livers are enriched for ‘Endothelium development’ and ‘Erythrocyte homeostasis’ transcriptional signatures.</title><p>Gene-set enrichment analysis (GSEA) was performed with the Java tool application available at the Broad Institute (Cambridge, MA, USA) in which FFPE micro-dissected RBC regions were compared with neighboring tissue. ES: enrichment score, NES: normalized enrichment score, NOM p-val: nominal p-value, FDR: false discovery rate, FWER p-val: familywise-error rate p-value. Transcriptomic gene-set enrichment analysis (GSEA) of hepatic peliosis (n = 4) relative to adjacent regions (n = 4) of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice showing endothelium and erythrocyte signatures. The table below is a GSEA using the hallmark database.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig2-figsupp1-v2.tif"/></fig></fig-group><p>We then analyzed the hematological parameters and complete blood cell counts from peripheral blood. RBC counts, as well as hematocrit and hemoglobin levels, were significantly higher in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice than in control or single knockout mice (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). This confirmed that blood erythrocytosis corresponded to erythrocyte overload.</p><p>The production of RBCs, known as erythropoiesis, is a dynamic process requiring the orchestration of specific molecular mechanisms (<xref ref-type="bibr" rid="bib40">Nogueira-Pedro et al., 2016</xref>). These include for example the key EPO cytokine, a circulating glycoprotein hormone (<xref ref-type="bibr" rid="bib25">Jelkmann, 2007</xref>). In mouse embryos, hepatoblasts are the primary source of Epo. In adults, the site of production switches from the liver to the kidney (<xref ref-type="bibr" rid="bib62">Weidemann and Johnson, 2009</xref>), but the adult liver can still produce Epo (<xref ref-type="bibr" rid="bib53">Suzuki, 2015</xref>). To determine whether erythrocytosis in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice could be due to dysregulation of this key hematological regulator, we examined <italic>Epo</italic> transcript and protein levels within the entire liver and the plasma fraction, respectively. We detected a marked reactivation of <italic>Epo</italic> expression in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> livers, whereas no Epo expression was detected in either single knockout or control livers (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). This was associated with distinctly higher Epo protein levels in the plasma of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2f</xref>). We confirmed that plasma Epo derived from the liver as we observed no change in Epo transcription in the kidneys of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). Interestingly, we saw no changes in Epo mRNA levels in human HCC harboring the compound <italic>CTNNB1</italic>/<italic>ARID1A</italic> mutations (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplements 4d</xref>).</p><p>Overall, our findings demonstrate that simultaneous <italic>Arid1a</italic> loss and β-catenin activation in single hepatocytes, occurring in a physiological but non-cancerous context, are responsible for a major hematological disorder that is linked to de novo expression and subsequent secretion of hepatic Epo.</p></sec><sec id="s2-3"><title>Erythropoiesis is induced in the spleens of [<italic>Apc-Arid1a</italic>] <sup>ko-focal</sup> mice</title><p>To determine the site of pathological production of the RBCs observed in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice, we examined the liver, bone marrow (BM), and spleen; these are the three major organs responsible for erythropoiesis during embryogenesis (<xref ref-type="bibr" rid="bib52">Suzuki et al., 2011</xref>), adult life (<xref ref-type="bibr" rid="bib53">Suzuki, 2015</xref>), and stress responses in mice (<xref ref-type="bibr" rid="bib41">Perry et al., 2009</xref>), respectively. Firstly, gross dissection of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice revealed a marked splenomegaly (<xref ref-type="fig" rid="fig3">Figure 3a,b</xref>). Histological sections from [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> spleens showed prominent expansion of the red pulp with a predominance of erythroblasts relative to control spleens (<xref ref-type="fig" rid="fig3">Figure 3c</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Erythropoiesis occurs in the spleen of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice.</title><p>(<bold>a</bold>) Gross morphology of spleens from representative control (WT) and [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice; (<bold>b</bold>) Spleen/body weight ratio of WT (n = 7), [<italic>Apc</italic>]<sup>ko-focal</sup> (n = 11), [<italic>Arid1a</italic>]<sup>ko-focal</sup> (n = 11), and [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> (n = 17) mice (one-way ANOVA). (<bold>c</bold>) Hematoxylin and Eosin staining of splenic sections. Scale bar is 200 µm. (<bold>d,e</bold>) FACS analysis of liver NPC, bone marrow, and spleens from control (WT) or [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice using the erythroid markers CD71 and Ter119. (<bold>e</bold>) FACS quantification from WT (n = 4) and [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> (n = 4) mice (multiple t-test). (<bold>f</bold>) Quantification of erythroid progenitors as erythroid colony-forming units (CFU-E) in the presence of EPO, using 2 × 10<sup>5</sup> cells from bone marrow or 2 × 10<sup>6</sup> cells from the liver and spleen of WT or [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice (2-way ANOVA). (<bold>g</bold>) Q-PCR showing relative expression of several factors, known to be involved in stress-induced erythropoiesis, in the spleens of WT (n = 9), [<italic>Apc</italic>]<sup>ko-focal</sup> (n = 5), [<italic>Arid1a</italic>]<sup>ko-focal</sup> (n = 8), and [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> (n = 8) mice (one-way ANOVA). ****p&lt;0.0001. Related data are found in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref> and source data in ‘<xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>'.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Spleen to body weight (<xref ref-type="fig" rid="fig3">Figure 3b</xref>), FACS analyses (<xref ref-type="fig" rid="fig3">Figure 3e</xref>), CFU-E counts (<xref ref-type="fig" rid="fig3">Figure 3f</xref>) and gene expression (<xref ref-type="fig" rid="fig3">Figure 3g</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Hepato-specific and focal inactivation of <italic>Apc</italic> and <italic>Arid1a</italic> genes leads to sequestration of enucleated beta-globin-positive red blood cells.</title><p>Western blot (<bold>a</bold>) and immunostaining (<bold>b, c</bold>) of hemoglobin subunit beta (Hbb) showing that Hbb-positive erythroid cells accumulated in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> livers are not nucleated, so do not correspond to immature and proliferative erythroblasts. Scale bars = 52 μm (b, c: bottom panel) or 200 μm (c: top panel).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig3-figsupp1-v2.tif"/></fig></fig-group><p>We additionally quantified erythroid precursors in the liver, BM, and spleen by flow cytometry (corresponding to the TER119<sup>+</sup>/CD71<sup>+</sup> cell population). In [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> liver non-parenchymal cells (NPCs) relative to controls, there was no difference in TER119<sup>+</sup>/CD71<sup>+</sup> progenitors revealing no intra-hepatic erythropoiesis (<xref ref-type="fig" rid="fig3">Figure 3d,e</xref>). However, there was a striking increase in the RBC population (TER119<sup>+</sup>/CD71<sup>-</sup>). This liver erythrocytosis was confirmed by immunostaining of the hemoglobin subunit beta (HBB) in liver tissue sections, showing that RBCs, but not erythroblasts, accumulated in these livers (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>). In addition, TER119<sup>+</sup>/CD71<sup>+</sup> cell populations were similar in the BM of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> and control mice, whereas we found threefold more erythroid precursors in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> spleens than in control spleens (<xref ref-type="fig" rid="fig3">Figure 3d,e</xref>). This suggested that RBC overproduction came from splenic and not from medullary or hepatic erythroblasts. We then analyzed the ability of erythroid progenitors to expand by in vitro quantification of erythroid colony-forming units (CFU-E) from spleen cells, BM cells, and liver NPCs. We confirmed the presence of erythroid progenitors in the BM and spleens of control mice after 3 days of culture in the presence of EPO, and their absence in control liver NPCs (<xref ref-type="fig" rid="fig3">Figure 3f</xref>). After EPO treatment, the spleens of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice contained 13-fold more CFU-E than control spleens (<xref ref-type="fig" rid="fig3">Figure 3f</xref>). This was not the case for the liver or BM. Finally, there were higher mRNA levels of erythropoiesis-related signaling components (<xref ref-type="bibr" rid="bib40">Nogueira-Pedro et al., 2016</xref>) in the spleens of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice than those of control or single knockout mice (<xref ref-type="fig" rid="fig3">Figure 3g</xref>), including that of the Epo receptor.</p><p>Overall, these data show a strong increase in erythropoiesis and erythrocyte progenitors in the spleens of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice.</p></sec><sec id="s2-4"><title>Blocking Epo signaling reverses erythrocytosis and splenic erythropoiesis, but maintains liver angiogenesis</title><p>We analyzed the role of Epo in the dramatic phenotype of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice. We used an anti-EPO blocking serum which neutralizes soluble erythropoietin in mice (<xref ref-type="bibr" rid="bib33">Mastrogiannaki et al., 2012</xref>). Anti-Epo treatment restored the hematocrit level of [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice to that of untreated controls (<xref ref-type="fig" rid="fig4">Figure 4a</xref>, <xref ref-type="fig" rid="fig2">Figure 2d</xref>), showing a reversal of blood erythrocytosis. We quantified 10-fold less erythroid precursors and a lower mRNA expression of erythropoiesis factors in the spleen of anti-Epo treated [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice compared to untreated mice (<xref ref-type="fig" rid="fig4">Figure 4b–d</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Blockade of Epo signaling with anti-EPO serum in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice eliminates aberrant erythropoiesis in the spleen, but maintains angiogenesis in the liver.</title><p>(<bold>a</bold>) Hematocrit before (n = 4) and after (n = 4) anti-EPO treatment (t-test). (<bold>b,c</bold>) FACS analysis (<bold>b</bold>) and quantification (<bold>c</bold>) of spleens with/without anti-EPO (n = 4 for each group) (t-test). (<bold>d</bold>) RT-qPCR showing relative expression of erythropoiesis factors in the spleens of WT (n = 9), treated [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> (n = 4), untreated [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> (n = 8) mice (one-way ANOVA). (<bold>e</bold>) Hematoxylin Eosin (HE)-stained sections of livers from representative 7-month-old mice. (<bold>f,g</bold>) FACS analysis (<bold>f</bold>) and quantification (<bold>g</bold>) of liver NPC with/without anti-EPO. (<bold>h</bold>) RT-qPCR showing relative expression of angiogenic factors in the livers with (n = 4) and without (n = 10) anti-EPO (t-test). ****p&lt;0.0001. Related data are found in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and source data in ‘<xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>'.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Hematocrit (<xref ref-type="fig" rid="fig4">Figure 4a</xref>), FACS quantifications (<xref ref-type="fig" rid="fig4">Figure 4c, g</xref>) and gene expression (<xref ref-type="fig" rid="fig4">Figure 4d, h</xref>) after anti-EPO treatment.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Anti-EPO blocking serum treatment in [<italic>Apc-Arid1a</italic>]<italic><sup>ko-focal</sup></italic> mice leads to decrease of intra-hepatic red blood cells accumulation.</title><p>Hematoxylin Eosin (HE)-stained sections of livers from untreated and treated 7-month-old [<italic>Apc-Arid1a</italic>]<italic><sup>ko-focal</sup></italic> mice with anti-EPO blocking serum. Scale bars = 200 μm. The dotted outlines correspond to increasing magnification showed in <xref ref-type="fig" rid="fig4">Figure 4f</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig4-figsupp1-v2.tif"/></fig></fig-group><p>EPO is a pleiotropic growth factor which can stimulate vessel growth through an autocrine and/or paracrine loop (<xref ref-type="bibr" rid="bib29">Kimáková et al., 2017</xref>). We tested the attractive possibility that hepatocyte-secreted Epo in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mouse livers regulates RBC homing to the liver through increased angiogenesis. Liver tissue sections showed that blood vessels contained less RBCs in anti-EPO treated [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice compared to untreated mice (<xref ref-type="fig" rid="fig4">Figure 4e</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>), and these livers harbored less TER119<sup>+</sup>/CD71<sup>-</sup> mature RBCs (<xref ref-type="fig" rid="fig4">Figure 4f–g</xref>). Despite this decrease in intrahepatic RBCs, we did not observe any change in the disruption of the liver vascular architecture as shown by both histological (<xref ref-type="fig" rid="fig4">Figure 4e</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>) and gene expression analyses (<xref ref-type="fig" rid="fig4">Figure 4h</xref>).</p><p>We demonstrate here that high plasma Epo concentration is directly responsible for splenic erythropoiesis and erythrocytosis in [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice. However, this cytokine alone is not responsible for alterations in liver angiogenesis.</p></sec><sec id="s2-5"><title><italic>Epo</italic> is cell-autonomously expressed by β-catenin-activated <italic>Arid1a</italic>-null hepatocytes in both the mouse and in humans</title><p>We investigated whether <italic>Epo</italic> is expressed by hepatocytes after <italic>Apc</italic> and/or <italic>Arid1a</italic> hepato-specific inactivations. We generated Tamoxifen-induced mouse models (<xref ref-type="fig" rid="fig5">Figure 5a</xref>) with short-term panlobular gene inactivations (<xref ref-type="fig" rid="fig5">Figure 5b</xref>) and <italic>Apc</italic> loss-induced hepatomegaly (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1a</xref>) as previously shown (<xref ref-type="bibr" rid="bib8">Buenrostro et al., 2015</xref>). After diet-based Tamoxifen administration, the <italic>Apc</italic> and/or <italic>Arid1a</italic> genes were invalidated in approximately 90% of hepatocytes (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1b</xref>). There was no gene invalidation in liver NPCs, thus highlighting the high purity of the NPC fraction (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplements 2a</xref>). We detected <italic>Epo</italic> mRNA expression only in the hepatocyte compartment and not in NPCs of [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> livers, whereas a slight decrease of Epo expression was seen in the kidney of [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5c,d</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Cell-autonomous <italic>Epo</italic> expression after <italic>Arid1a</italic> inactivation and Wnt/β-catenin activation in murine and human hepatocytes.</title><p>(<bold>a</bold>) In vivo and ex vivo strategy. WT (n = 8), [<italic>Apc</italic>]<sup>ko-TOTAL</sup> (n = 7), [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 8), and [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 10) mice. (<bold>b</bold>) Inactivation efficiency of <italic>Apc</italic> and <italic>Arid1a</italic> genes in isolated hepatocytes. (<bold>c,d</bold>) RT-qPCR assessment of erythropoietin (<italic>Epo</italic>) transcription (<bold>c</bold>) in the hepatocyte and NPC compartments of the livers, (<bold>d</bold>) in the kidney (1-way ANOVA). (<bold>e</bold>) In vitro analysis of <italic>Axin2</italic>, <italic>Arid1a</italic> (<italic>Arid1a</italic> floxed-exon detection), and <italic>Epo</italic> expression by RT-qPCR of mouse hepatocytes after Wnt3a and R-Spondin3 stimulation, and si-Arid1a/si-Control treatments, showing <italic>Arid1a</italic> knockdown efficiency and Wnt/β-catenin pathway activation, as the mRNA levels of <italic>Axin2</italic>, a canonical target gene of Wnt signaling, significantly increased (2-way ANOVA). (<bold>f</bold>) In vitro analysis of <italic>Apc</italic>, <italic>Arid1a</italic>, and <italic>Epo</italic> by RT-qPCR of cryopreserved human hepatocytes after siRNA transfection (one-way ANOVA analysis). Data are presented as the mean ± SEM. ****p&lt;0.0001. Cell culture data are representative of three independent experiments. Related data are found in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s2">2</xref>, and source data in ‘<xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>; <xref ref-type="supplementary-material" rid="fig5s1sdata1">Figure 5—figure supplement 1—source data 1</xref>; <xref ref-type="supplementary-material" rid="fig5s2sdata1">Figure 5—figure supplement 2—source data 1</xref>’.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Efficiency of gene invalidation (<xref ref-type="fig" rid="fig5">Figure 5b</xref>), and gene expression in vivo and ex vivo (<xref ref-type="fig" rid="fig5">Figure 5c-f</xref>) in mice and humans.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Panlobular inactivation of <italic>Apc</italic> and/or <italic>Arid1a</italic> in hepatocytes.</title><p>(<bold>a</bold>) Hepatomegaly in mice after panlobular inactivations. WT (n = 30), [<italic>Apc</italic>]<sup>ko-TOTAL</sup> (n = 9), [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 9), and [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 14) mice. Data are presented as the mean + SEM and analyzed using one-way ANOVA. (<bold>b</bold>) Immunostaining of glutamine synthetase (Glul) and Arid1a after <italic>Apc</italic> and/or <italic>Arid1a</italic> loss in all hepatocytes in mouse liver. Note the physiological staining of Glul surrounding the centrilobular vein (cv) in WT and [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup> livers and the remaining nonparenchymal staining of Arid1a after hepato-specific <italic>Arid1a</italic> inactivation ([<italic>Arid1a</italic>]<sup>KO-TOTAL</sup> and [<italic>Apc-Arid1a</italic>]<sup>KO-TOTAL</sup>). Apc loss leads to overactivation of the Wnt/β-catenin pathway and, consequently, increased Glul staining of hepatocytes to the whole lobule. Scale bars = 200 μm.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Liver to body weight ratio (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1a</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Cell-autonomous <italic>Epo</italic> expression after <italic>Arid1a</italic> invalidation and Wnt/β-catenin activation in hepatocytes.</title><p>(<bold>a</bold>) No invalidation of <italic>Apc</italic> and <italic>Arid1a</italic> genes was found in NPC from [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> mice (Student t-test). (<bold>b</bold>) In vitro analysis of <italic>Axin2</italic>, <italic>Arid1a,</italic> and <italic>Epo</italic> transcription by RT-qPCR in primary culture hepatocytes after siRNA-mediated knockdown of <italic>Arid1a</italic> (siArid1a, 20 nM) and Wnt3a and R-Spondin3 stimulation (Wnt/RSpo) relative to that of control hepatocytes. (<bold>c</bold>) In vitro expression of <italic>Axin2</italic>, <italic>Arid1a,</italic> and <italic>Epo</italic> in isolated [<italic>Apc</italic>]<italic>ko-TOTAL</italic> hepatocytes after siArid1a. (<bold>d</bold>) In vitro expression of <italic>Apc</italic>, <italic>Arid1a</italic>, and <italic>Epo</italic> in the HEPA1.6 β-catenin-mutated hepatoma murine cell line after siRNA-mediated knockdown of <italic>Arid1a</italic> and/or β-catenin. (<bold>e,f</bold>) Western blot of Arid1a and beta-catenin demonstrating effective siRNA-mediated knockdown of <italic>Arid1a</italic> (20 nM) and Wnt/Spondin stimulation in primary culture hepatocytes (<bold>e</bold>) and effective inactivation of <italic>Apc</italic> and/or <italic>Arid1a</italic> in vivo (<bold>f</bold>). Data are presented as the mean ± SEM and analyzed with one-way ANOVA. ****p&lt;0.0001. Cell culture data are representative of three independent experiments carried out in triplicate.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Efficiency of gene invalidation (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplements 2a</xref>), mRNA expression (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplements 2b-d</xref>), western blots (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplements 2e</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig5-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig5-figsupp2-v2.tif"/></fig></fig-group><p>To confirm the cell-autonomous expression of <italic>Epo</italic> in β-catenin-activated <italic>Arid1a</italic>-null hepatocytes, we performed RNA in situ hybridization for <italic>Epo</italic> with <italic>Axin2</italic> as a marker of β-catenin activation (<xref ref-type="fig" rid="fig6">Figure 6</xref>). <italic>Epo</italic> transcripts were not expressed in the livers, yet were abundant in rare interstitial renal cells of control mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplements 1a</xref>); this localization of <italic>Epo</italic> in the kidney has already been described (<xref ref-type="bibr" rid="bib31">Lacombe et al., 1988</xref>). Conversely but as expected, we found <italic>Axin2</italic> mRNA transcripts in pericentral hepatocytes (<xref ref-type="bibr" rid="bib5">Benhamouche et al., 2006</xref>). After <italic>Apc</italic> and <italic>Arid1a</italic> gene invalidation, we found a de novo expression of <italic>Epo</italic> in a subset of <italic>Axin2</italic>-expressing hepatocytes. In the long-term focal model, this expression was restricted to the areas of peliosis (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). In the short-term panlobular model, rare <italic>Axin2</italic>-expressing hepatocytes also expressed single <italic>Epo</italic> mRNA transcripts (<xref ref-type="fig" rid="fig6">Figure 6b</xref>). In both models, <italic>Epo</italic> expression was not found elsewhere in the liver.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>In situ hybridization of mRNAs showing a de novo expression of Epo in a subset of β-catenin-activated hepatocytes.</title><p>(<bold>a</bold>) Seven months after Apc/Arid1a gene invalidation in single hepatocytes from two livers (#1 and #2); (<bold>b</bold>) 7 days after gene invalidation in more than 90% hepatocytes (two livers: #a and #b). Axin2 RNAScope probe stains β-catenin-activated hepatocytes (blue dots), and Epo RNAScope probe stains single Epo mRNAs as red dots. Related data are found in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Implementation of in situ Hybridization for Axin2 and Epo mRNAs using RNAScope, showing expressing mRNA as dots.</title><p>(<bold>a,b</bold>) Ppib (blue) and Polr2a (red) were successfully found expressed in liver and kidney FFPE sections of control mice. No expression of bacterial dapB was found. (<bold>c</bold>) In control livers, Axin2 mRNAs (blue) were restricted to the hepatocytes surrounding the central vein as a consequence of Wnt signaling in that area. No Epo was expressed. (<bold>d</bold>) In control kidneys, Epo mRNAs (red) were abundantly detected in rare interstitial cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig6-figsupp1-v2.tif"/></fig></fig-group><p>We examined whether <italic>Epo</italic> expression is specific to the loss of <italic>Apc</italic> or can be initiated regardless of how Wnt/β-catenin signaling is activated. We successfully activated β-catenin via its Wnt/Spondin ligand in murine primary hepatocytes (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplements 2e</xref>). We consecutively performed in vivo Arid1a knockout followed by in vitro Wnt/Spondin stimulation, or in vivo Apc loss followed by efficient in vitro siRNA-mediated <italic>Arid1a</italic> knockdown (si-Arid1a) (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplements 2f</xref>). <italic>Epo</italic> expression significantly increased in these conditions (<xref ref-type="fig" rid="fig5">Figure 5e</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplements 2b, c</xref>). Mutational activation of β-catenin coupled with si-<italic>Arid1a</italic> also led to the induction of <italic>Epo</italic> expression in the β-catenin-mutated HEPA1.6 murine hepatoma-derived cell line (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplements 2d</xref>).</p><p>We assessed the conservation of EPO regulation from mouse to humans. We found that <italic>EPO</italic> mRNA expression was also regulated by both the chromatin remodeler ARID1A and the Wnt/β-catenin signaling pathway in primary human hepatocytes after siRNA-mediated <italic>ARID1A</italic> and <italic>APC</italic> downregulation (<xref ref-type="fig" rid="fig5">Figure 5f</xref>).</p><p>Overall, these in vivo and in vitro findings strongly demonstrate a conserved and cell-autonomous role of Wnt/β-catenin activation and <italic>Arid1a</italic> loss in hepatic <italic>Epo</italic> expression. This occurs as a stochastic transcriptional event in β-catenin-activated <italic>Arid1a</italic>-null hepatocytes.</p></sec><sec id="s2-6"><title>Wnt/β-catenin pathway control of 3’ <italic>Epo</italic> enhancer activity is hypoxia- and HIF-independent</title><p>We questioned if β-catenin directly controls <italic>Epo</italic> transcription through cis-regulatory sequences. We previously performed ChIP-Seq experiments to assess Tcf4/β-catenin occupancy in the chromatin of hepatocytes isolated from [<italic>Apc</italic>]<sup>ko-TOTAL</sup><italic>versus</italic> [<italic>β-catenin</italic>]<sup>ko-TOTAL</sup> murine models (<xref ref-type="bibr" rid="bib18">Gougelet et al., 2014</xref>). The only DNA region bound by Tcf4 in the vicinity of the <italic>Epo</italic> gene was its 3’enhancer (<italic>Epo</italic>-3’E), known to be involved in <italic>Epo</italic> transcription in the embryonic liver, as well as the known Hif- (HIF-REs) and Hnf4-containing responses elements (HREs) (<xref ref-type="bibr" rid="bib52">Suzuki et al., 2011</xref>; <xref ref-type="bibr" rid="bib45">Semenza et al., 1991</xref>; <xref ref-type="fig" rid="fig7">Figure 7a</xref>). This Tcf4 binding was at the same location as HRE binding, and was stronger in activated β-catenin than in β-catenin-null hepatocytes (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). We demonstrated from ENCODE data that H3K27Ac, a histone mark indicating active promoters or enhancers, also bound to this region; this binding was present in mouse liver chromatin at E14.5, an embryonic stage in which the <italic>Epo</italic> gene is actively transcribed (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). However, <italic>Epo</italic> was only partially present in the livers of eight-week-old mice, with no <italic>Epo</italic> transcription, and completely absent in the adult small intestine, a tissue known not to transcribe the <italic>Epo</italic> gene (<xref ref-type="fig" rid="fig7">Figure 7a</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Wnt/β-catenin directly controls EPO expression through 3’ <italic>Epo</italic> enhancer, in a HIF-independent manner.</title><p>(<bold>a</bold>) Genomic environment of the <italic>Epo</italic> gene (UCSC Genome Browser, mm9 database) and ChIP-seq peaks at the 3’ <italic>Epo</italic> enhancer. In blue/red: the crude reads of ChIP-Seq data performed in adult livers against HNF-4a (54). In black: ChIP-Seq under Apc<sup>ko</sup> or βcat<sup>ko</sup> conditions with an antibody against TCF4 (16). In yellow: ENCODE data of H3K27Ac marks in eight-week-old and E14.5 embryonic livers (Histone Mods by ChIP-Seq from ENCODE/LICR). (<bold>b</bold>) Schematic representation of the EpoE-Luc erythropoietin luciferase reporter, driven by the 3’ enhancer. (<bold>c–e</bold>) Luciferase reporter assays in mouse primary hepatocytes: (<bold>c</bold>) after in vitro overactivation of Wnt/β-catenin signaling and Arid1a knockdown (<bold>d</bold>) after in vivo Cre-loxP-mediated gene inactivation; (<bold>e</bold>) Effect of hypoxic-mimic conditions using desferrioxamine (DFO), and effect of knockdown of HIF factors (two separate experiments carried out in triplicate). Results are in relative light units, and analyzed using 1-way (<bold>d</bold>) or 2-way ANOVA (<bold>c,e</bold>). ****p&lt;0.0001. Related data are found in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplements 1</xref>–<xref ref-type="fig" rid="fig7s2">2</xref>, and source data in ‘<xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>; <xref ref-type="supplementary-material" rid="fig7s1sdata1">Figure 7—figure supplement 1—source data 1</xref>; <xref ref-type="supplementary-material" rid="fig7s2sdata1">Figure 7—figure supplement 2—source data 1</xref>’.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>EpoE-luc luciferase relative activity (<xref ref-type="fig" rid="fig7">Figure 7c-e</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Lack of hypoxia and HIF signaling in [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> livers.</title><p>(<bold>a</bold>) Immunodetection of hepatic hypoxia seven days after <italic>Apc</italic> and/or <italic>Arid1a</italic> loss in all hepatocytes in mouse liver. For hypoxia detection in tissues, mice were injected with Hypoxyprobe (NPI Inc) solution via intraperitoneal injection (60 mg/100 g body weight), and livers harvested 1 hr after. Paraffin sections were processed according to the manufacturer’s instructions (Hypoxyprobe-1 Kit). Note the physiological staining surrounding the centrilobular vein (cv) in all conditions. No pathological and extended hypoxia was detected. Scale bars = 200 μm. (<bold>b,c</bold>) Western blots of Arid1a, Glul, Hif2α, and actin (<bold>b</bold>), and Hif2α detection quantification (n = 2 for each genotype) (<bold>c</bold>) showing no Hif2α stabilization in either condition. (<bold>d</bold>) RT-qPCR analysis of Hif1α and Hif2α target gene expression in livers of 2-month-old mice, 1 week after panlobular <italic>Apc</italic> and <italic>Arid1a</italic> invalidation. WT (n = 8), [<italic>Apc</italic>]<sup>ko-TOTAL</sup> (n = 8), [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 7), and [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 8) mice. One-way ANOVA tests were done. ns = non significant.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Quantification of western blots (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplements 1c</xref>) and mRNA expression (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplements 1d-e</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig7-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Effect of HIF1α and HIF2α knock-downs in mouse primary and transgenic hepatocytes.</title><p>(<bold>a</bold>) RT-qPCR analysis of Hif1α and Hif2α expression in primary culture hepatocytes treated or not with desferrioxamine (DFO) and after siRNA mediated knockdown of <italic>Hif1α</italic> (20 nM) and/or <italic>Hif2α</italic> (20 nM). (<bold>b</bold>) Western blots of Hif1α, Hif2α, and actin showing that Hif1α and Hif2α were stabilized in presence of DFO and that siRNA-mediated knockdown against Hif1α, Hif2α were effective. (<bold>c,d</bold>) RT-qPCR analysis of Hif1α (<bold>c</bold>) and Hif2α (<bold>d</bold>) in primary culture hepatocytes from livers of 2-month-old mice. Experiments were performed 1 week after panlobular inactivation of <italic>Apc</italic> and/or <italic>Arid1a</italic> and 48 hr after siRNA mediated knockdown of <italic>Hif1α</italic> (20 nM) and/or <italic>Hif2α</italic> (20 nM). (<bold>e</bold>) Western blots of Arid1a, Hif1α, Hif2α, Glul and Actin showing that no increase of Hif1α and Hif2α was detected in primary culture hepatocytes from [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> mice compared to control ones. 1,2: WT; 3,4: [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup>; 5,6: [<italic>Apc</italic>]<sup>ko-TOTAL</sup>; 7,8: [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup>. Data are presented as the mean ± SEM and analyzed by one-way ANOVA ****p&lt;0.0001. Cell culture data are representative of two independent experiments, each performed in technical triplicate.</p><p><supplementary-material id="fig7s2sdata1"><label>Figure 7—figure supplement 2—source data 1.</label><caption><title>mRNA expressions (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplements 2a, c, d</xref>) and western blots (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplements 2b, e</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig7-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig7-figsupp2-v2.tif"/></fig></fig-group><p>We thus tested whether Wnt/β-catenin signaling directly activates hepatic <italic>Epo</italic> transcription through the <italic>Epo</italic>-3’E. We transfected a luciferase reporter (pEpoE-luc) containing the HIF and HNF4-binding sites into primary mouse hepatocytes (<xref ref-type="fig" rid="fig7">Figure 7b</xref>). After Wnt/Spondin stimulation, and regardless of si-<italic>Arid1a</italic> treatment, <italic>Epo</italic> enhancer activity was five- to eight-fold higher (<xref ref-type="fig" rid="fig7">Figure 7c,d</xref>). Hence, in this in vitro reporter assay context, β-catenin signaling increases <italic>Epo-</italic>3’E activity and it is independent of the chromatin landscape.</p><p>Hypoxia-inducible factor (HIF) signaling is the master pathway regulating <italic>EPO</italic> transcription and Hif2α has a prominent role in hepatic <italic>Epo</italic> transcription (<xref ref-type="bibr" rid="bib33">Mastrogiannaki et al., 2012</xref>). We investigated Hif2α involvement in β-catenin/Arid1a-dependent <italic>Epo</italic> expression. In vivo, we did not detect hypoxia or Hif1α/Hif2α accumulation in the absence of <italic>Apc</italic> and/or <italic>Arid1a</italic> in mouse livers (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplements 1a-c</xref>). A small subset of Hif1α/Hif2α targets, such as Eno2, Car9, and Rab42, was slightly overexpressed in both [Apc]<sup>ko</sup> and [Apc-Arid1a]<sup>ko</sup> livers, confirming that β-catenin and HIF signaling share some transcriptional targets (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplements 1d-e</xref>; <xref ref-type="bibr" rid="bib5">Benhamouche et al., 2006</xref>). As expected, the hypoxia-mimetic agent desferrioxamine (DFO) markedly potentiated luciferase activity in pEpoE-luc-transfected hepatocytes, whereas efficient knockdown of both <italic>Hif1α</italic> or <italic>Hif2α</italic> (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplements 2</xref>) resulted in a significant decrease (<xref ref-type="fig" rid="fig7">Figure 7e</xref>). Interestingly, knockdown of <italic>HIFs</italic>, either alone or combined, did not reduce <italic>Epo-3’E</italic> induction by β-catenin signaling in hepatocytes, whether <italic>Apc</italic> be inactivated alone or in combination with <italic>Arid1a</italic> (<xref ref-type="fig" rid="fig7">Figure 7e</xref>).</p><p>In all, the Wnt/β-catenin pathway controls erythropoietin expression in hepatocytes through the 3’ <italic>Epo</italic> enhancer in a hypoxia- and HIF-independent manner.</p></sec><sec id="s2-7"><title>Both β-catenin signaling and Arid1a are key players in chromatin remodeling, histone recruitment, and Tcf4 binding on the hepatic <italic>Epo</italic> enhancer</title><p>We previously showed similarities between HREs and WREs, and that Tcf4 can bind HREs and thereby participate in β-catenin-dependent transcription (<xref ref-type="bibr" rid="bib18">Gougelet et al., 2014</xref>). Here, we found that Tcf4 bound DNA on the HRE region of the Epo-3’E in which there is no classical WRE. Indeed, by electrophoretic mobility shift assay (EMSA), we showed that Tcf4 weakly bound the <italic>Epo</italic>-3’E HRE (thereafter called DR2) in control liver nuclear extracts (<xref ref-type="fig" rid="fig8">Figure 8a</xref>). In [<italic>Apc</italic>]<sup>ko-TOTAL</sup> liver extracts, the nuclear translocation of β-catenin led to a stronger binding represented by a supershift (<xref ref-type="fig" rid="fig8">Figure 8a,b</xref>). This indicates that the Tcf4/β-catenin complex binds this DR2 motif, as well as a classical WRE shown by competitive EMSA (<xref ref-type="fig" rid="fig8">Figure 8b,c</xref>). These findings highlighted that Tcf4 binds to the HRE of the <italic>Epo</italic> enhancer and that activation of β-catenin increases this interaction.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>β-catenin/Tcf4 complex binds to the HNF4-responsive element of Epo enhancer (Epo-HRE) after modifications of histone marks and chromatin accessibility.</title><p>(<bold>a</bold>) EMSA using nuclear proteic extracts from WT or [<italic>Apc</italic>]<sup>ko-TOTAL</sup> livers and <sup>32</sup>P-labeled probes containing Epo-HRE (DR2). (<bold>b, c</bold>) Competitive EMSA using <sup>32</sup>P-labeled DR2 (<bold>b</bold>) and <sup>32</sup>P-labeled WRE (<bold>c</bold>) probes and increasing concentrations of cold probes containing HNF4, WRE or control-responsive element. WRE cold probes compete with radiolabeled DR2 motif for the Tcf4/β-catenin binding and vice versa. (<bold>d, e</bold>) Chromatin ImmunoPrecipitation (ChIP) assays of hepatocytes from WT, [<italic>Apc</italic>]<sup>ko-TOTAL</sup>, [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup>, and [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> livers. ChIP-qPCR against IgG, Tcf4, Acetylation of Histone3 in Lysine27 (H3K27Ac), and Tri-methylation of Histone3 in Lysine27 (H3K27me3) for <italic>Axin2</italic> (<bold>d</bold>) and <italic>Epo</italic> (<bold>e</bold>) enhancer regions. WT (n = 3), [<italic>Apc</italic>]<sup>ko-TOTAL</sup> (n = 2), [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 2), and [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 3) mice. Enrichment by ChIP was assessed relative to the input DNA and normalized to the level of negative controls. (<bold>f</bold>) ATAC-qPCR using frozen livers from WT (n = 7), [<italic>Apc</italic>]<sup>ko-TOTAL</sup> (n = 7), [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 6), and [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 7) mice. Data are analyzed with one-way ANOVA. ****p&lt;0.0001. Related data are found in <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplements 1</xref>–<xref ref-type="fig" rid="fig8s2">2</xref>, and source data in ‘<xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>; <xref ref-type="supplementary-material" rid="fig8s2sdata1">Figure 8—figure supplement 2—source data 1</xref>; <xref ref-type="supplementary-material" rid="fig8s2sdata1">Figure 8—figure supplement 2—source data 1</xref>’.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>EMSA (<xref ref-type="fig" rid="fig8">Figure 8a-c</xref>), ChIP-qPCR (<xref ref-type="fig" rid="fig8">Figure 8d, e</xref>) and ATAC-qPCR (<xref ref-type="fig" rid="fig8">Figure 8f</xref>) data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>The expression of β-catenin-positive target genes is not modulated by Arid1a status.</title><p>RT-qPCR analysis of GS and Axin2 expression in hepatocytes from the livers of two-month-old mice, one week after panlobular <italic>Apc</italic> and <italic>Arid1a</italic> invalidation. WT (n = 3), [<italic>Apc</italic>]<sup>ko-TOTAL</sup> (n = 2), [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup> (n = 2), and [<italic>Apc- Arid1a</italic>]ko<sup>-TOTAL</sup> (n = 3) mice. Data are presented as the mean + SEM and analyzed with one-way ANOVA.</p><p><supplementary-material id="fig8s1sdata1"><label>Figure 8—figure supplement 1—source data 1.</label><caption><title>mRNA expression (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplements 1a</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig8-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig8-figsupp1-v2.tif"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 2.</label><caption><title>Chromatin accessibility assessed all along the hepatic 3’Epo enhancer by ATAC-qPCR.</title><p>(<bold>a</bold>) The hepatic 3’ Epo enhancer with the 4 PCR products analyzed: the whole hepatic 3’ Epo enhancer (222nt); (1) the EPO-enh-5’ located upstream the HIF- and Hnf4- responsive elements; (2) the EPO-enhHIF centered on the HIF-responsive element; (3) the EPO-enhHnf4 centered on the Hnf4 responsive element. In any case, the chromatin from Apc<sup>ko</sup> hepatocytes is more accessible compared to WT chromatin, and the highest accessibility occurs on EPO-enhHnf4 both for [<italic>Apc</italic>]<sup>ko-TOTAL</sup> and [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> chromatin. Data are analyzed with two-way ANOVA. ****p&lt;0.0001.</p><p><supplementary-material id="fig8s2sdata1"><label>Figure 8—figure supplement 2—source data 1.</label><caption><title>ATAC-qPCR data (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplements 2b</xref>).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53550-fig8-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig8-figsupp2-v2.tif"/></fig></fig-group><p>Endogenous hepatic <italic>Epo</italic> was expressed de novo after both Wnt/β-catenin activation and <italic>Arid1a</italic> knockout, but gene expression of classical β-catenin target genes (<italic>Glul</italic>, <italic>Axin2</italic>) was not affected by Arid1a status (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplements 1</xref>). We thus characterized Tcf4 binding, chromatin accessibility, and histone active (H3K27Ac) or repressive (H3K27Me3) marks of the Epo enhancer, the Axin2 intronic enhancer, and the Glul promoter in hepatocytes isolated from transgenic mouse livers.</p><p>As previously described (<xref ref-type="bibr" rid="bib18">Gougelet et al., 2014</xref>), Tcf4 efficiently bound to the <italic>Axin2</italic> intronic enhancer in vivo and this increased when β-catenin signaling was activated (<xref ref-type="fig" rid="fig8">Figure 8d</xref>). This was correlated with a partial removal of the repressive H3K27Me3 mark (<xref ref-type="fig" rid="fig8">Figure 8d</xref>) and an increase in chromatin accessibility revealed by ATAC-qPCR analysis (<xref ref-type="fig" rid="fig8">Figure 8f</xref>). Co-inactivation of <italic>Arid1a</italic> and <italic>Apc</italic> decreased chromatin accessibility on this enhancer and induced a H3K27me3 repressive histone mark. A similar chromatin accessibility profile was seen for the Glul promoter. Tcf4 bound in vivo to the <italic>Epo</italic> enhancer, and this binding was slightly higher in [<italic>Apc</italic>]<sup>ko-TOTAL</sup> and much higher in [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> hepatocytes versus controls (<xref ref-type="fig" rid="fig8">Figure 8e</xref>). After <italic>Apc</italic> loss, the H3K27me3 repressive mark slightly decreased on <italic>Epo</italic> enhancer and chromatin was more accessible (<xref ref-type="fig" rid="fig8">Figure 8f</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplements 1b</xref>). In contrast, the loss of Arid1a strongly decreased the H3K27Me3 repressive mark without modifying chromatin access. In [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> hepatocytes, the H3K27Ac active histone mark was induced while chromatin accessibility was lower compared to single knockout hepatocytes.</p><p>These data show that nuclear β-catenin favors Tcf4 binding on the <italic>Epo</italic> enhancer, increasing its chromatin accessibility, whereas <italic>Arid1a</italic> loss rather disrupts the H3K27me3 histone repressive mark. Both these changes increase the H3K27Ac enhancer mark and promote hepatic <italic>Epo</italic> transcription (<xref ref-type="fig" rid="fig9">Figure 9</xref>).</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Schematic model of the role of <italic>Arid1a</italic> in hepatic <italic>Epo</italic> expression linked to overactivation of the Wnt/β-catenin pathway.</title><p>Under physiological conditions, the presence of Arid1a is associated with histone repressive marks at the <italic>Epo</italic> enhancer and β-catenin is constantly degraded; thus, Epo is not produced. In the absence of Apc, β-catenin/Tcf4 complex binds the <italic>Epo</italic> enhancer, and enhances chromatin accessibility, but the histone marks remain repressive. The loss of <italic>Arid1a</italic> increases active histone marks, which is insufficient to induce <italic>Epo</italic> transcription. After both Wnt/β-catenin activation and Arid1a inactivation, active histone marks and binding of β-catenin/Tcf4 to the <italic>Epo</italic> enhancer drive <italic>Epo</italic> liver transcription, and subsequent secretion of Epo into the bloodstream, resulting in splenic erythropoiesis and in substantial blood and liver erythrocytosis.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53550-fig9-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our study shows that the Arid1a-dependent epigenetic landscape in the adult liver is a potent brake for transcription of EPO, a new key β-catenin target (<xref ref-type="fig" rid="fig9">Figure 9</xref>). Consequently, <italic>Arid1a</italic> loss in the context of β-catenin activation leads to Epo-dependent erythropoiesis in the spleen, erythrocytosis in the blood and liver, and to increased but defective angiogenesis, generating ‘peliosis’.</p><p>Liver peliosis is a misunderstood human vascular disease, with non-specific features of impaired blood inflow and/or systemic inflammatory response (<xref ref-type="bibr" rid="bib59">Valla and Cazals-Hatem, 2018</xref>). The dramatic phenotype we observed here is distinct from other existing murine models of liver-induced hypoxia with equivalent non-lethal erythrocytosis (<xref ref-type="bibr" rid="bib36">Minamishima and Kaelin, 2010</xref>; <xref ref-type="bibr" rid="bib44">Ruschitzka et al., 2000</xref>; <xref ref-type="bibr" rid="bib54">Takeda et al., 2008</xref>). Using an anti-Epo blocking strategy, we could explain this discrepancy: our phenotypic observations were attributable to not only Epo-dependent erythrocytosis, as restricting plasma Epo rescued the erythrocytosis phenotype, but also to Epo-independent aberrant angiogenesis, a hallmark of liver peliosis (<xref ref-type="bibr" rid="bib59">Valla and Cazals-Hatem, 2018</xref>).</p><p>We describe emerging roles for ARID1A and β-catenin signalings in <italic>Epo</italic> transcription. Until now, the major known regulator of both renal and hepatic <italic>Epo</italic> transcription was hypoxia-inducible factor signaling, acting via EPO’s 3’ enhancer (Epo-3’E) in the embryonic liver or anemic/hypoxic adult liver. We demonstrated that Tcf4/β-catenin bound the Hnf4-Responsive Element (Hnf4-RE) in the Epo-3’E and that the enhancer activity is independent of HIF in this context, contrary to what is reported in colorectal cancer cell lines, in which transcriptional cooperation between HIF and β-catenin occurs in hypoxia adaptation (<xref ref-type="bibr" rid="bib27">Kaidi et al., 2007</xref>).</p><p>The consequences of this HIF signaling-independent <italic>Epo</italic> regulation is significant for the genetic engineering of EPO for therapeutic purposes. In anemia, a major complication of chronic kidney disease, HIF stabilizers are currently used to restore circulating EPO levels. The long-term safety of this strategy is hindered by the lack of targeting specificity (<xref ref-type="bibr" rid="bib30">Kular and Macdougall, 2019</xref>). The use of cell transcriptional machinery to produce therapeutic levels of EPO has been put forward to overcome the side effects associated with HIF stabilizers. The EPO-producing cells of the adult kidney are potential candidates, but anemic patients have damaged kidneys. Based on our results, here we can propose an alternative involving the restoration of the ability of hepatocytes to synthetize EPO, independently of hypoxia, by targeting Wnt/β-catenin and ARID1A signaling in the liver.</p><p>Our demonstration that <italic>Arid1a</italic> inactivation is required in <italic>Epo</italic> transcription opposes previously described roles of chromatin remodeling complexes in hepatic regulation of <italic>Epo</italic> (<xref ref-type="bibr" rid="bib61">Wang et al., 2004</xref>; <xref ref-type="bibr" rid="bib46">Sena et al., 2013</xref>). However, firstly these studies analyzed hypoxia-dependent Epo regulation which is distinct from our study; we firmly established that the β-catenin-dependent control of <italic>Epo</italic> transcription depends on <italic>Arid1a</italic> loss, is Hif-independent, and occurs in a normoxic adult liver. Secondly, these studies focused on BRG1/BRM ATPases, essential core subunits of both the BAF and pBAF complexes. The loss of <italic>Arid1a</italic>, a facultative component of the BAF complex, does not disrupt BAF complex functionality as Arid1b is known to compensate for Arid1a loss. This highlights a specific role for Arid1a in transcriptional repression through the modulation of chromatin accessibility to transcription factors at their target DNA sequences (<xref ref-type="bibr" rid="bib50">Sun et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Nagl et al., 2005</xref>). We show increased binding of the Tcf4/β-catenin complex to Epo-3’E Hnf4-RE is <italic>Arid1a</italic>-dependent and <italic>Arid1a</italic> loss decreases the H3K27me3 repressive mark. That could be due to the intricate balance existing between the Polycomb complex PRC2 and the SWI/SNF complex (<xref ref-type="bibr" rid="bib26">Kadoch et al., 2016</xref>). Accordingly, the inhibition of the Polycomb EZH2 subunit is synthetically lethal in ARID1A-mutated tumors (<xref ref-type="bibr" rid="bib6">Bitler et al., 2015</xref>; <xref ref-type="bibr" rid="bib1">Alldredge and Eskander, 2017</xref>). Therefore, Arid1a and the Polycomb complex could act in concert to modulate <italic>Epo</italic> gene expression in the liver.</p><p>We illustrate that <italic>Arid1a</italic> loss renders the liver <italic>Epo</italic>-inducible element more accessible to Tcf4, and even more so to β-catenin. Contrary to the paradigm that Tcf4 binds its DNA targets regardless of β-catenin activation status, we previously reported that Tcf4 DNA-binding was stronger in the presence of nuclear β-catenin in the liver (<xref ref-type="bibr" rid="bib18">Gougelet et al., 2014</xref>). More broadly, numerous interactions between chromatin remodeling and Wnt/β-catenin signaling have already been described (<xref ref-type="bibr" rid="bib4">Barker et al., 2001</xref>; <xref ref-type="bibr" rid="bib16">Eckey et al., 2012</xref>; <xref ref-type="bibr" rid="bib34">Mathur et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Song et al., 2009</xref>; <xref ref-type="bibr" rid="bib63">Yan et al., 2014</xref>; <xref ref-type="bibr" rid="bib65">Zhai et al., 2016</xref>) and can explain the impact of β-catenin signaling on chromatin accessibility at the <italic>Epo</italic> enhancer. Single-RNA in situ hybridization revealed that <italic>Epo</italic> gene expression only occurs in rare hepatocytes, emphasizing the complexity of Epo liver transcription in the liver. This contributes to previous studies using single-RNA in situ hybridization, showing that transcription in the liver is gene-dependent, and is either bursty and dynamic or stable (<xref ref-type="bibr" rid="bib3">Bahar Halpern et al., 2015</xref>).</p><p>We found here that the loss of Arid1a does not change the transcription of hepatic canonical Wnt/β-catenin target genes. As for <italic>Epo</italic>, it could potentially unmask new chromatin-dependent β-catenin target genes. Among these new Arid1a/β-catenin target genes are those involved in liver angiogenesis. In the near future, genome-wide studies will be required to firmly identify these genes, combining the analysis of transcriptome, chromatin accessibility (ATAC-Seq), histone mark, β-catenin and Arid1a cistromes (ChIP-Seq) in liver chromatin from Arid1a-null and β-catenin-activated hepatocytes.</p><p>The initial aim of our study was to better elucidate oncogenic cooperation in liver carcinogenesis. In our in vivo experimental models reported here, the loss of Arid1a protects against β-catenin-dependent carcinogenesis. However, these results were not fully exploitable due to the deleterious effect of the dramatic hematological disorder developed by the mice. New mouse models are therefore required for further investigation of the oncogenic role of <italic>Arid1a</italic> in liver carcinogenesis. In turn, confirmation of such a role would corroborate a recent study showing that hepatic <italic>Arid1a</italic> can harbor either a tumor suppressor or oncogenic role depending on the cellular context (<xref ref-type="bibr" rid="bib51">Sun et al., 2018</xref>). An additional study also demonstrated that <italic>Arid1a</italic> is protumoral rather than a tumor suppressor in colorectal cancer with <italic>Apc</italic> mutations (<xref ref-type="bibr" rid="bib34">Mathur et al., 2017</xref>).</p><p>Lastly, some liver cancer studies have identified pathological erythrocytosis and/or hepatic vascular lesions, potentially with EPO production and peliosis. However, the molecular mechanisms underlying these pathological observations are still poorly understood (<xref ref-type="bibr" rid="bib35">Matsuyama et al., 2000</xref>; <xref ref-type="bibr" rid="bib9">Bunn, 2013</xref>; <xref ref-type="bibr" rid="bib28">Ke et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Hoshimoto et al., 2009</xref>; <xref ref-type="bibr" rid="bib58">Tsuchiya et al., 2009</xref>; <xref ref-type="bibr" rid="bib60">Vik et al., 2009</xref>). Our study contributes molecular clues by indicating that this is not linked to <italic>CTNNB1/ARID1A</italic> mutations, but more likely attributed to the hypoxia frequently found in cancers. Future studies should use mouse models and data from patients with HCC to address the specific transcriptional output of <italic>CTNNB1/ARID1A-</italic>mutated liver tumors.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent <break/>type <break/>(species) or <break/>resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Gene (<italic>Mus musculus</italic>)</td><td valign="top">Epo</td><td valign="top">GenBank</td><td valign="top">NM_007942.2</td><td valign="top">Erythropoietin</td></tr><tr><td valign="top">Gene (<italic>Mus musculus)</italic></td><td valign="top">Arid1a</td><td valign="top">GenBank</td><td valign="top">NM_001080819.2</td><td valign="top">Arid1a</td></tr><tr><td valign="top">Gene (<italic>Mus musculus</italic>)</td><td valign="top">Ctnnb1</td><td valign="top">GenBank</td><td valign="top">NM_007614.3</td><td valign="top">Beta-catenin</td></tr><tr><td valign="top">Gene (<italic>Mus musculus</italic>)</td><td valign="top">Apc</td><td valign="top">GenBank</td><td valign="top">NM_001360980.1</td><td valign="top">Adenomatous polyposis coli</td></tr><tr><td valign="top">Strain, strain background (<italic>Mus musculus</italic>)</td><td valign="top">Arid1a-lox</td><td valign="top">From Z. Wang’s lab</td><td valign="top"><italic>Arid1a<sup>tm1.1Zhwa</sup></italic>/J</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.jax.org/strain/027717">https://www.jax.org/strain/027717</ext-link></td></tr><tr><td valign="top">Strain, strain background (<italic>Mus musculus</italic>)</td><td valign="top">Apc-lox</td><td valign="top">From Perret-Colnot’s lab</td><td valign="top">Apc<sup>tm2.1Cip</sup></td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.infrafrontier.eu/search?keyword=EM:05566">https://www.infrafrontier.eu/search?keyword=EM:05566</ext-link></td></tr><tr><td valign="top">Strain, strain background (<italic>Mus musculus</italic>)</td><td valign="top">Ttr-Cre-Tam</td><td valign="top">From Perret-Colnot’s lab</td><td valign="top">Tg(Ttr-cre/Esr1*)1Vco</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.infrafrontier.eu/search?keyword=EM:01713">https://www.infrafrontier.eu/search?keyword=EM:01713</ext-link></td></tr><tr><td valign="top">Genetic reagent (<italic>Adenovirus 5</italic>)</td><td valign="top">Ad-Cre</td><td valign="top">Université de Nantes, France</td><td valign="top">Ad5-CAG-Cre</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://umr1089.univ-nantes.fr/facilities-cores/cpv/translational-vector-core-2201753.kjsp?RH=1519296751975">https://umr1089.univ-nantes.fr/facilities-cores/cpv/translational-vector-core-2201753.kjsp?RH=1519296751975</ext-link></td></tr><tr><td valign="top">Cell line (<italic>Mus musculus</italic>)</td><td valign="top">Mouse hepatoma</td><td valign="top">From Christine Perret’s lab</td><td valign="top">Hepa 1-6 [Hepa1-6] (ATCC CRL-1830)</td><td valign="top">For transfection experiments</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-Arid1a (Rabbit monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# 182560 <break/>[EPR13501]</td><td valign="top">IHC(1:1000), WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-Glul (GS) (Mouse monoclonal)</td><td valign="top">BD Biosciences</td><td valign="top">Cat# 610518, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_397880">AB_397880</ext-link></td><td valign="top">IHC(1:400), WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-HBB (Mouse monoclonal)</td><td valign="top">Proteintech</td><td valign="top">Cat# 16216–1-AP, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10598329">AB_10598329</ext-link></td><td valign="top">IHC(1:200), WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-HIF1α (Rabbit polyclonal)</td><td valign="top">Novus</td><td valign="top">Cat# NB100-449, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10001045">AB_10001045</ext-link></td><td valign="top">WB nuclear extract (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-HIF2α (Rabbit polyclonal)</td><td valign="top">Novus</td><td valign="top">Cat# NB100-122, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10002593">AB_10002593</ext-link></td><td valign="top">WB nuclear extract (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Tcf4 (Tcf7l2) (Mouse monoclonal)</td><td valign="top">Millipore</td><td valign="top">Cat# 05–511, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_309772">AB_309772</ext-link></td><td valign="top">ChIP: 3 μg</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-H3K27Ac (Rabbit polyclonal)</td><td valign="top">Active Motif</td><td valign="top">Cat# 39133, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2561016">AB_2561016</ext-link></td><td valign="top">ChIP: 3 μg</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-H3K27me3 (Rabbit polyclonal)</td><td valign="top">Active Motif</td><td valign="top">Cat# 39155, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2561020">AB_2561020</ext-link></td><td valign="top">ChIP: 3 μg</td></tr><tr><td valign="top">Antibody</td><td valign="top">IgG (Mouse)</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 10400C, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2532980">AB_2532980</ext-link></td><td valign="top">ChIP: 3 μg</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-CD71-FITC (Rat monoclonal)</td><td valign="top">BD Biosciences</td><td valign="top">Cat# 553266, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_394743">AB_394743</ext-link></td><td valign="top">FACS (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Ter119-PE (rat monoclonal)</td><td valign="top">BD Biosciences</td><td valign="top">Cat# 553673, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_394986">AB_394986</ext-link></td><td valign="top">FACS (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-β-actin (mouse monoclonal)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# A5441, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_476744">AB_476744</ext-link></td><td valign="top">WB (1:10000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-lamin A/C (rabbit polyclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 2032, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2136278">AB_2136278</ext-link></td><td valign="top">WB nuclear extract (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">IgG, HRP-conjugated (horse, anti-mouse)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 7076, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_330924">AB_330924</ext-link></td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">IgG, HRP-conjugated (goat, anti-rabbit)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 7074, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2099233">AB_2099233</ext-link></td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">IgG, biotinylated (goat, anti-rabbit)</td><td valign="top">Vector lab</td><td valign="top">Cat# BA-1000, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2313606">AB_2313606</ext-link></td><td valign="top">IHC (1:200)</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">MOM mouse on mouse</td><td valign="top">Vector Laboratories</td><td valign="top">Cat# BMK-2202, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2336833">AB_2336833</ext-link></td><td valign="top">Kit</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">18S</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Taqman Assay 4308329</td><td valign="top">qPCR primers</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Glul</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Taqman Assay Mm00725701_si</td><td valign="top">qPCR primers <break/><italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Axin2</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Taqman Assay Mm00443610_m1</td><td valign="top">qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Arid1a (total)</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Taqman Assay Mm00473838_m1</td><td valign="top">qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Arid1a (not excised by Cre)</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Taqman Assay Mm00473841_m1</td><td valign="top">qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Apc (total)</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Taqman Assay Mm00545877_m1</td><td valign="top">qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Apc (not excised by Cre)</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Taqman Assay Mm01130462_m1</td><td valign="top">qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Epo</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Taqman Assay Mm01202755_m1</td><td valign="top">qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence- <break/>based reagent</td><td valign="top">18 s</td><td valign="top">Eurogentec</td><td valign="top">F_GTAACCCGTTGAACCCCATT <break/>R_CCATCCAATCGGTAGCG</td><td valign="top">SybrGreen qPCR primers</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Angiopoietin-like 2 (Angptl2)</td><td valign="top">Eurogentec</td><td valign="top">F_CCGCAACATGAACTCGAGAG <break/>R_GTGCTCCAGGTCCTTGTACT</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Carbonic anhydrase 9 (Car9)</td><td valign="top">Eurogentec</td><td valign="top">F_GACCTCGTGATTCTCGGCTA <break/>R_GAGAAGGCCAAACACCAAGG</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Cyclin D1 (Ccnd1)</td><td valign="top">Eurogentec</td><td valign="top">F_AGAAGTGCGAAGAGGAGGTC <break/>R_TTCTCGGCAGTCAAGGGAAT</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Enolase 2, gamma neuronal (Eno2)</td><td valign="top">Eurogentec</td><td valign="top">F_TGGATTTCAAGTCTCCCGCT <break/>R_TCAGGTCATCGCCCACTATC</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Erythropoietin receptor (Epo-r)</td><td valign="top">Eurogentec</td><td valign="top">F_ATGACTTTCGTGACTCACCCT <break/>R_GGGCTCCGAAGAACTTCTGTG</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">FMS-like tyrosine kinase 1 (Flt1)</td><td valign="top">Eurogentec</td><td valign="top">F_AGAGGAGGATGAGGGTGTCT <break/>R_GGGAACTTCATCTGGGTCCA</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">GATA binding protein 1 (Gata1)</td><td valign="top">Eurogentec</td><td valign="top">F_TTCCCACTACTGCTGCTACC <break/>R_GCGGCCTCTATTTCAAGCTC</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">GATA binding protein 2 (Gata2)</td><td valign="top">Eurogentec</td><td valign="top">F_GCCGGTTCTGTCCATTCATC <break/>R_ATGGCAGCAGTCTCTTCCAT</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Inhibin beta-B (Inhbb)</td><td valign="top">Eurogentec</td><td valign="top">F_GTACCTGAAACTGCTCCCCT <break/>R_ATGGCCTCTGTGATGGGAAA</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Potassium channel tetramer domain contain. 11 (Kctd11)</td><td valign="top">Eurogentec</td><td valign="top">F_TGACTTCTACCAGATCCGGC <break/>R_TCAGGGTCAGTGCAGAAGAG</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence- <break/>based reagent</td><td valign="top">Kinase insert domain protein receptor (Kdr)</td><td valign="top">Eurogentec</td><td valign="top">F_AGAAGATGCCCATGACCCAA <break/>R_TCACCCATCCTCAACACACA</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Nuclear factor, erythroid derived 2 (Nfe2)</td><td valign="top">Eurogentec</td><td valign="top">F_GATGTCCCGAACTAGAGCCA <break/>R_ACACCCTTGGCCTTAGAGTC</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Platelet derived growth factor receptor, alpha polypeptide (Pdgfra)</td><td valign="top">Eurogentec</td><td valign="top">F_ACAGCTCACAGACTTCGGAA <break/>R_AGAAGATGATACCCGGAGCG</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Phosphoglycerate kinase 1 (Pgk1)</td><td valign="top">Eurogentec</td><td valign="top">F_TGGCACCAGGAACCCTTAAA <break/>R_AGCTCAGCCTTTACAGCTCA</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Placenta-specific 8 (Plac8)</td><td valign="top">Eurogentec</td><td valign="top">F_TGATTGCTTCAGTGACTGCG <break/>R_GTTCATGGCTCTCCTCCTGT</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Protein tyrosine phosphatase, receptor type, B (Ptprb)</td><td valign="top">Eurogentec</td><td valign="top">F_TGGACCCTGGGATCTAAGGA <break/>R_GTGGTCACTGCAAGCTTCAA</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Member RAS oncogene family (Rab42)</td><td valign="top">Eurogentec</td><td valign="top">F_GGCGTTCTGTTGGTCTTTGA <break/>R_GCAAGTTCCTCTGCTTCCTG</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Vascular endothelial growth factor A (Vegfa)</td><td valign="top">Eurogentec</td><td valign="top">F_GCTGTAACGATGAAGCCCTG <break/>R_CGCTCCAGGATTTAAACCGG</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Zinc finger protein, multitype 1 (Zfpm1)</td><td valign="top">Eurogentec</td><td valign="top">F_CCTTGAGATGGCGTTCACAG <break/>R_CCTGCTCTACTACTGTGCCA</td><td valign="top">SybrGreen qPCR primers <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">AT-rich interaction domain 1A (ARID1A)</td><td valign="top">Eurogentec</td><td valign="top">F_AAGCCACCAACTCCAGCATCCA <break/>R_CGCTTCTGGAATGTGGAGTCAC</td><td valign="top">SybrGreen qPCR primers (<italic>Homo sapiens</italic>)</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Adenomatous polyposis coli (APC)</td><td valign="top">Eurogentec</td><td valign="top">F_CACACTTCCAACTTCTCGCAACG <break/>R_AGGCTGCATGAGAGCACTTGTG</td><td valign="top">SybrGreen qPCR primers (<italic>Homo sapiens</italic>)</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Erythropoietin (EPO)</td><td valign="top">Eurogentec</td><td valign="top">F_GCATGTGGATAAAGCCGTCAGTG <break/>R_GAGTTTGCGGAAAGTGTCAGCAG</td><td valign="top">SybrGreen qPCR primers (<italic>Homo sapiens</italic>)</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">DOS7-binding site (Control)</td><td valign="top">Eurogentec</td><td valign="top">F_GGGGTAGGAACCAATGAAA <break/>R_TTTCATTGGTTCCTACCCC</td><td valign="top">EMSA probe <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HNF4-responsive element (DR2)</td><td valign="top">Eurogentec</td><td valign="top">F_GCCCGGCTGACCTCTTGACCCCTCTGGGCTTGAG <break/>R_CTCAAGCCCAGAGGGGTCAAGAGGTCAGCCGGGC</td><td valign="top">EMSA probe <italic>Mus musculus</italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Wnt-reponsive element</td><td valign="top">Eurogentec</td><td valign="top">F_CATCCCCCTTTGATCTTACC <break/>R_GGTAAGATCAAAGGGGGATG</td><td valign="top">EMSA probe</td></tr><tr><td valign="top">Sequence- <break/>based reagent</td><td valign="top">Negative control region</td><td valign="top">Eurogentec</td><td valign="top">F_ACACACCTTGAATCCCGT <break/>R_CCCAGCTAGAATGAACAAG</td><td valign="top">qPCR primers for ChIP and ATAC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Hepatic Epo 3’ enhancer</td><td valign="top">Eurogentec</td><td valign="top">F_CTGTACCTCACCCCATCTGGTC <break/>R_CCCAGCTCACTCAGCACTTGTCC</td><td valign="top">qPCR primers for ChIP and ATAC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">EPO-enh-5’ (1)</td><td valign="top">Eurogentec</td><td valign="top">F_GGCAACAGCTGAAATCACCAA <break/>R_TCCCAGATCTGATGCCTTGC</td><td valign="top">qPCR primers for ATAC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">EPO-enhHIF (2)</td><td valign="top">Eurogentec</td><td valign="top">F_CTGTACCTCACCCCATCTGG <break/>R_CAGAGGGGTCAAGAGGTCAG</td><td valign="top">qPCR primers for ChIP and ATAC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">EPO-enhHnf4 (3)</td><td valign="top">Eurogentec</td><td valign="top">F_GCAAGGCATCAGATCTGGGA <break/>R_AGACAGCCTTGAATGGAGCC</td><td valign="top">qPCR primers for ChIP and ATAC</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>Mice carrying two floxed alleles in the 14th exon of the <italic>Apc</italic> gene (generated in our laboratory [<xref ref-type="bibr" rid="bib11">Colnot et al., 2004</xref>]) or the 8th exon of the <italic>Arid1a</italic> gene (created by the Zhong Wang laboratory [<xref ref-type="bibr" rid="bib17">Gao et al., 2008</xref>]),were interbred with TTR-Cre<sup>Tam</sup> mice (<xref ref-type="bibr" rid="bib55">Tannour-Louet et al., 2002</xref>), resulting in <italic>Apc</italic><sup>flox/+</sup>/TTR-Cre<sup>Tam</sup> or <italic>Arid1a</italic><sup>flox/+</sup>/TTR-Cre<sup>Tam</sup> mice. For focal genetic inactivation, 8-week-old <italic>Apc</italic><sup>flox/flox</sup> and <italic>Arid1a</italic><sup>flox/flox</sup> male mice were injected intravenously with 0.5 × 10<sup>9</sup> infectious particles of Ad5-CAG-cre (AdCre) adenovirus as described (<xref ref-type="bibr" rid="bib11">Colnot et al., 2004</xref>). Mice with hepato-specific and AdCre-mediated inactivation of <italic>Apc</italic> and/or <italic>Arid1a</italic> in single hepatocytes are referred to as [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup>, [<italic>Apc</italic>]<sup>ko-focal</sup>, and [<italic>Arid1a</italic>]<sup>ko-focal</sup> mice. The development of tumors and peliosis were followed monthly by 2D-ultrasound (Vevo 770, Visualsonics). For panlobular genetic inactivation, 8-week-old <italic>Apc</italic><sup>flox/flox</sup>/Ttr-Cre<sup>Tam</sup> and <italic>Arid1a</italic><sup>flox/flox</sup>/Ttr-Cre<sup>Tam</sup>male mice were given a tamoxifen diet (M-Z, low phytoestrogen +1000 mg/kg TAM citrate, SSNIFF, Soest, Germany) for 4 days. These mice are referred to as [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup>, [<italic>Apc</italic>]<sup>ko-TOTAL</sup>, and [<italic>Arid1a</italic>]<sup>ko-TOTAL</sup> mice.</p><p>Mice were housed under conventional conditions and all reported animal procedures were carried out according to French government regulations (Ethics Committee of Descartes University, Paris). The animal welfare assurance number is APAFIS#14472.</p></sec><sec id="s4-2"><title>Immunohistochemistry and in situ hybridization experiments</title><p>After sacrifice, livers were harvested, fixed overnight in 4% formalin buffer, and embedded in paraffin. FFPE liver sections were treated as previously described for immunocytochemistry and HE stainings (<xref ref-type="bibr" rid="bib14">de La Coste et al., 1998</xref>). Antibodies used are listed in the Key Resources Table.</p><p>RNA in situ hybridization was done on freshly cut 7 μm FFPE liver or kidney sections using the RNAScope 2.5 HD Duplex Kit, with HybEZ II hybridization system, following the manufacturer’s instructions (Advanced Cell Diagnostics). The following RNAscope probes were used: Epo (Mm-Epo-C2, Cat. 315501-C2, NM_007942.2, region 39–685), Axin2 (Mm-Axin2, Cat. 400331, NM_015732.4, region 330–1287), DapB (negative control, Cat. 320751, CP015375.1, region 2252107–2252555), Polr2a (positive control, Mm-Polr2a, Cat. 320761, NM_001291068.1, region 3212–4088).</p></sec><sec id="s4-3"><title>Hematological analysis and red blood cell counts</title><p>Hematological parameters were measured using a CoulterMAXM automatic analyzer (Beckman Coulter) as previously described (<xref ref-type="bibr" rid="bib32">Mastrogiannaki et al., 2009</xref>).</p></sec><sec id="s4-4"><title>Plasma collection and ELISA for erythropoietin</title><p>At sacrifice, peripheral blood was collected from the <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Inferior_vena_cava">inferior vena cava</ext-link> with a heparinized needle (Sigma Aldrich – H3393-50KU). Plasma samples were stored at −80°C. Plasma EPO protein levels were determined using a Quantikine mouse EPO enzyme-linked immunosorbent assay kit (R and D systems – MEP00B), according to the manufacturer’s instructions.</p></sec><sec id="s4-5"><title>Treatment with anti-erythropoietin blocking serum</title><p>One-year-old [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> and control mice were injected with anti-erythropoietin rabbit serum, as previously described (<xref ref-type="bibr" rid="bib33">Mastrogiannaki et al., 2012</xref>), with minor modifications: injections were performed for 7 consecutive days and mice were sacrificed 18 hr after the last injection. The dose injected was described as able to neutralize a 10-fold excess of circulating erythropoietin (<xref ref-type="bibr" rid="bib33">Mastrogiannaki et al., 2012</xref>). At sacrifice, liver and spleen were collected for immunochemistry and cytometry analysis.</p></sec><sec id="s4-6"><title>Hepatocyte isolation and cell culture</title><p>Livers from 3-month-old mice were perfused 7 days after the beginning of the tamoxifen diet (1000 mg/kg) with collagenase. The liver cell suspension was collected, and hepatocytes were separated from NPCs by centrifugation for 2 min at 48 g as previously described (<xref ref-type="bibr" rid="bib2">Anson et al., 2012</xref>). The supernatant containing the NPCs was collected and centrifuged for 10 min at 440 g. Hepatocytes were plated as previously described (<xref ref-type="bibr" rid="bib18">Gougelet et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Torre et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">Guidotti et al., 2003</xref>). Hepa1-6 hepatoma cell line was a gift from C. Perret's lab, authenticated by its <italic>CTNNB1</italic> mutation, assessed by Sanger sequencing. It was tested negative for mycoplasma contamination. Cells were plated at 3 × 10<sup>5</sup> cells per well, in six-well plates, in DMEM solution supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and fungizone.</p><p>Cryopreserved human hepatocytes were obtained from Triangle Research Laboratory (Lonza). They were seeded at confluency (2.1 10<sup>5</sup> cell/cm²) and cultured in a humidified 5% CO<sub>2</sub> atmosphere at 37°C in hepatocyte growth medium (HGM: WME medium supplemented with 5 µg/ml insulin, 0.1 µM hydrocortisone, 10 µg/ml transferrin, 250 µg/ml ascorbic acid, 3.75 mg/ml fatty-acid-free bovine serum albumin, 2 mM glutamine, penicillin and streptomycin).</p></sec><sec id="s4-7"><title>Cell transfection, stimulation, and luciferase assays</title><p>Primary murine hepatocytes were transfected with 20 nM small-interfering RNA (siRNA) directed against Arid1a (Qiagen SI00230405) or control siRNA (Dharmacon D-001210-01-05) in the presence of Lipofectamine 2000 (Thermo Fisher Scientific). The next day, cells were stimulated, or not, with 100 ng/ml recombinant mouse Wnt3a (1324-WN) and 100 ng/ml recombinant mouse R-Spondin 3 Protein (4120-RS) (R and D Systems). Molecular analyses were performed 48 hr after transfection or stimulation.</p><p>HEPA 1.6 cells were transfected for 24 and 48 hr with 20 nM siRNA directed against <italic>Arid1a</italic> or β-catenin (QiagenSI00942039) or control siRNA. Molecular analyses were performed 72 hr after the first transfection.</p><p>Adherent primary human hepatocytes were transfected with 20 nM non-targeting siRNA or siRNAs specific for <italic>APC</italic> (Dharmacon, Lafayette, CO) or <italic>ARID1A</italic> (Qiagen 1027416) at day 1 and day 3 after seeding, using Lipofectamine RNAiMAX (Life Technologies, Carlsbad, CA).</p><p>For luciferase assay, primary mouse hepatocytes were transfected using Lipofectamine 2000 (ThermoFisher Scientific) with 1 μg of a luciferase reporter driven by erythropoietin 3’ enhancer region (Epo-3’E, 50 nucleotides) (<xref ref-type="bibr" rid="bib24">Huang et al., 1996</xref>), and/or 500 ng of a Renilla vector (Promega, Madison, WI). Luciferase activity was measured 48 hr after transfection with the Dual-Luc kit, according to manufacturer’s protocols (Promega).</p></sec><sec id="s4-8"><title>Isolation of peliosis-like areas from paraffin-embedded (FFPE) tissue sections and Affymetrix microarrays</title><p>Healthy and peliosis-like areas were isolated from 15 to 20 paraffin sections (10 µm) using a small needle under a binocular magnifying glass. After deparaffinization, FFPE tissues were lysed for 24 hr in tissue lysis with proteinase K (Qiagen) at 60°C. Microarray transcriptomic analysis from paraffin-embedded (FFPE) tissue sections was performed on the MTA-31461 chip. Gene set enrichment analysis (GSEA) was performed using the Java tool application available at the Broad Institute (Cambridge, MA, USA). The analysis was performed using Hallmark gene data sets.</p></sec><sec id="s4-9"><title>RNA extraction and quantitative RT-PCR</title><p>Total RNA was extracted with Trizol reagent (Thermo Fisher Scientific) as previously described (<xref ref-type="bibr" rid="bib19">Gougelet et al., 2016</xref>). Reverse transcription was performed from 100 ng RNA with a cDNA synthesis kit from Thermo Scientific (K1642). The Taqman assays (Thermo Fisher Scientific) and the sequences of PCR primers (Eurogentec) for SybrGreen assays are described in the Key Resources Table. qPCR was performed in duplicate on a LightCycler480 apparatus and the results, analyzed by the ΔΔCt technique, expressed relative to those for 18S RNA.</p></sec><sec id="s4-10"><title>Calculation of gene inactivation efficiencies</title><p>Arid1a and Apc mRNAs were analyzed by RT-qPCR. For each gene, we used two distinct Taqman assays: (1) One contained two primers both located in undeleted regions. It allowed to detect both wild type and inactivated genes, so the relative mRNA expression of ‘TOTAL’ gene; (2) In the other, one primer was located in the deleted region. Thus, this Taqman assay allowed to detect and amplify only the ‘non excised’ gene. We quantified the percentage of inactivation as follows: % of gene inactivation = (1- (mRNA expression of TOTAL <italic>gene expression</italic>/mRNA expression of undeleted <italic>gene expression</italic>)) x 100.</p></sec><sec id="s4-11"><title>Protein extracts and western blotting</title><p>Livers were lysed mechanically in RIPA buffer (Sigma Aldrich – R0278-50ml) with protease inhibitors (Roche - 11697498001), and boiled in Laemmli sample buffer (Sigma Aldrich – S3401-1VL). 50 µg of protein per lane were run on 8% polyacrylamide gels. The resulting protein bands were electrotransferred onto a 0.2 µm nitrocellulose membrane (Biorad 162–0112), which was then blocked with 5% blocking reagent (Biorad 170–6404) in TBS/Tween 0.1% for 1 hr at RT, probed overnight with the primary antibody, and then incubated with IgG HRP-conjugated secondary antibody for detection with the Clarity ECL substrate (Biorad 70–5061).</p><p>To analyze nuclear protein extracts, livers were lysed in Hepes 10 mM pH7.9, KCl 10 mM, EDTA 0.1 mM, EGTA 0.1 mM, DTT 1 mM, AEBSF 0.5 mM. Then, after addition of 12,5 µl of NP40 20% and centrifugation, the pellet was resuspended in Hepes 20 mM pH7.9, NaCl400 mM, EDTA 1 mM, EGTA 1 mM, DTT 1 mM, AEBSF 1 mM, PIC1X, Glycerol 5%, and the supernatants boiled in Laemmli. We next ran 70 µg of protein per lane on Bolt 4–12% Bis-TrisPlus Gels (Thermo Fisher, NW04125BOX). Detection was performed by using Super Signal West Dura ECL system (Thermo Fisher, 34076).</p></sec><sec id="s4-12"><title>Electrophoretic mobility shift assay (EMSA)</title><p>Nuclear proteins preparation and LXR electromobility shift assay (EMSA) were performed as previously described (<xref ref-type="bibr" rid="bib7">Bobard et al., 2005</xref>). The probes are listed in the Key Resources Table. The HRE element from the Epo-3’E is constituted from two direct repeats of GG/AGTCA sequences with a spacing of two nucleotides (thereafter called DR2).</p></sec><sec id="s4-13"><title>Flow cytometry and c-forming unit-erythroid (CFU-E) assays</title><p>Primary mouse bone marrow, spleen cells, and NPC liver cells were harvested from [<italic>Apc-Arid1a</italic>]<sup>ko-focal</sup> mice and their wild-type littermates and erythroid cell populations were identified and analysed using CD71/TER119 flow-cytometric assay. Staining was performed in a 96-well plate and samples (5.10<sup>4</sup> cells) were washed once in PBS, 0.4% BSA, 0.1% Sodium Azide, sample staining volume was 50 µl of mix primary-antibody solution, to a final concentration 1.0 × 10<sup>6</sup> cells/ml. Primary antibody staining mix were prepared for CD71-FITC and Ter119-PE. Unstained cells, Isotype Ig and single stained cells were used as control and to define boundaries between negative and positive cell labelling. After incubation in the primary antibody stain, two washes were performed by adding 200 µl of staining buffer to each sample.</p><p>For CFU-E formation, we plated in duplicate 2 × 10<sup>5</sup> bone marrow cells or 2 × 10<sup>6</sup> splenic/NPC liver cells in MethoCult M3234 (StemCell Technologies), supplemented, or not, with 2 U EPO. The number of CFU-E colonies was counted after 3 days.</p></sec><sec id="s4-14"><title>Chromatin immunoprecipitation (ChIP) and ATAC-qPCR assays</title><p>ChIP assay was previously described for hepatocytes isolated after collagenase perfusion in <xref ref-type="bibr" rid="bib18">Gougelet et al., 2014</xref>. Chromatin was immunoprecipitated using 3 µg antibody preabsorbed onto 60 µl protein G agarose (Thermo Fisher Scientific – 10004D). Bindings were assessed on the Axin2 intronic enhancer and hepatic Epo enhancer, relative to that of the immunoglobulin isotype control, by Taqman assay and SYBR green technology, respectively with the following oligonucleotides (Eurogentec): negative control region and hepatic Epo enhancer. Enrichment by ChIP was assessed relative to the input DNA and normalized to the level of the negative controls.</p><p>ATAC-qPCR assays were done using omni-ATAC as described in <xref ref-type="bibr" rid="bib13">Corces et al., 2017</xref>, on frozen liver samples after isolation of nuclei. Then, 50,000 nuclei were used for transposition for 30 min in 50 μl reaction mix containing 2.5 μl transposase (Illumina kit #FC-121–103), digitonin and tween 20 at 0.1%. After transposition, the following steps were done according to the initial protocol (<xref ref-type="bibr" rid="bib8">Buenrostro et al., 2015</xref>). The qPCR step was similar to ChIP experiments.</p></sec><sec id="s4-15"><title>Statistics</title><p>We assessed statistical significances with GraphPad Prism six software. The data represent the mean ± SEM and p values were calculated by two-tailed unpaired Student’s t-test, one-way ANOVA, or two-way ANOVA as specified in the figure legends. p&lt;0.05 was considered statistically signiﬁcant and exact p-values are mentioned unless ****p&lt;0.0001. Each quantitative experiment was repeated at least three times. We considered biological replicates as those animals or tissues subjected to the same experimental test, and technical replicates as individual samples or tissues subjected to the same analysis.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the French National League against Cancer (LNCC), by the IDEX ‘Epilivcan’, by the Institut National du Cancer ‘Epigenetics and Liver Cancer’, and by the Plan-Cancer Programme « CHROMA-LIV ». RR got fellowships from the French Laboratory of Excellence program ‘Who am I ?” (no ANR-11-LABX-0071 included in the Investments for the Future program n° ANR-11-IDEX-0005–01), and the French Foundation for Cancer Research (ARC). We are thankful to Dr C Peyssonnaux team for discussions on erythropoietin expression, and help to measure hematological blood parameters. We are thankful to Dr P Mayeux, JC Deschemin and Dr E Huang for the gift of anti-EPO blocking serum, DFO and EpoE-LUC plasmid, respectively. We wish to thank the animal housing facility at Cochin Institute, and the ‘GENOM’IC’ facility for transcriptomic data generation and analysis. We are very grateful to Dr C Desbois-Mouthon, Dr S Vaulont and Pr J Weitzman for critical reading of the manuscript, and to Pr J Weitzman, Pr J Zucman-Rossi and Dr C Desdouets for helpful discussions.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con2"><p>Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Supervision, Validation, Visualization</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation, Involved in the revision process</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation, Involved in the revision process</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Supervision, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: This study was performed in strict accordance with the French government regulations. All of the animals were handled according to approved institutional animal care and use committee (Ethics Committee of Descartes University, Paris). The protocol was approved by the Ethics Committee of Descartes University, Paris (permit number APAFIS#14472). Every effort was made to minimize suffering.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-53550-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Microarrays have been deposited in GEO database (GSE134553) and are publicly available. All data generated or analysed during this study are included in the manuscript and supporting files. Source data excel files have been provided for Figures 1, 2, 3, 4, 5, 7, 8, 1S1,1S3,3S1,5S1,5S2,7S1.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Colnot</surname><given-names>S</given-names></name><name><surname>Riou</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Expression data from isolated areas from [Apc-Arid1a]ko-focal liver tissues after FFPE treatment</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134553">GSE134553</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alldredge</surname> <given-names>JK</given-names></name><name><surname>Eskander</surname> <given-names>RN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>EZH2 inhibition in <italic>ARID1A</italic> mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers</article-title><source>Gynecologic Oncology Research and Practice</source><volume>4</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1186/s40661-017-0052-y</pub-id><pub-id pub-id-type="pmid">29093822</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anson</surname> <given-names>M</given-names></name><name><surname>Crain-Denoyelle</surname> <given-names>AM</given-names></name><name><surname>Baud</surname> <given-names>V</given-names></name><name><surname>Chereau</surname> <given-names>F</given-names></name><name><surname>Gougelet</surname> <given-names>A</given-names></name><name><surname>Terris</surname> <given-names>B</given-names></name><name><surname>Yamagoe</surname> <given-names>S</given-names></name><name><surname>Colnot</surname> <given-names>S</given-names></name><name><surname>Viguier</surname> <given-names>M</given-names></name><name><surname>Perret</surname> <given-names>C</given-names></name><name><surname>Couty</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice</article-title><source>Journal of Clinical Investigation</source><volume>122</volume><fpage>586</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1172/JCI43937</pub-id><pub-id pub-id-type="pmid">22251704</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahar Halpern</surname> <given-names>K</given-names></name><name><surname>Tanami</surname> <given-names>S</given-names></name><name><surname>Landen</surname> <given-names>S</given-names></name><name><surname>Chapal</surname> <given-names>M</given-names></name><name><surname>Szlak</surname> <given-names>L</given-names></name><name><surname>Hutzler</surname> <given-names>A</given-names></name><name><surname>Nizhberg</surname> <given-names>A</given-names></name><name><surname>Itzkovitz</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bursty gene expression in the intact mammalian liver</article-title><source>Molecular Cell</source><volume>58</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.01.027</pub-id><pub-id pub-id-type="pmid">25728770</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname> <given-names>N</given-names></name><name><surname>Hurlstone</surname> <given-names>A</given-names></name><name><surname>Musisi</surname> <given-names>H</given-names></name><name><surname>Miles</surname> <given-names>A</given-names></name><name><surname>Bienz</surname> <given-names>M</given-names></name><name><surname>Clevers</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation</article-title><source>The EMBO Journal</source><volume>20</volume><fpage>4935</fpage><lpage>4943</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.17.4935</pub-id><pub-id pub-id-type="pmid">11532957</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benhamouche</surname> <given-names>S</given-names></name><name><surname>Decaens</surname> <given-names>T</given-names></name><name><surname>Godard</surname> <given-names>C</given-names></name><name><surname>Chambrey</surname> <given-names>R</given-names></name><name><surname>Rickman</surname> <given-names>DS</given-names></name><name><surname>Moinard</surname> <given-names>C</given-names></name><name><surname>Vasseur-Cognet</surname> <given-names>M</given-names></name><name><surname>Kuo</surname> <given-names>CJ</given-names></name><name><surname>Kahn</surname> <given-names>A</given-names></name><name><surname>Perret</surname> <given-names>C</given-names></name><name><surname>Colnot</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Apc tumor suppressor gene is the &quot;zonation-keeper&quot; of mouse liver</article-title><source>Developmental Cell</source><volume>10</volume><fpage>759</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2006.03.015</pub-id><pub-id pub-id-type="pmid">16740478</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitler</surname> <given-names>BG</given-names></name><name><surname>Aird</surname> <given-names>KM</given-names></name><name><surname>Garipov</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Amatangelo</surname> <given-names>M</given-names></name><name><surname>Kossenkov</surname> <given-names>AV</given-names></name><name><surname>Schultz</surname> <given-names>DC</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Shih</surname> <given-names>I</given-names></name><name><surname>Conejo-Garcia</surname> <given-names>JR</given-names></name><name><surname>Speicher</surname> <given-names>DW</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers</article-title><source>Nature Medicine</source><volume>21</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1038/nm.3799</pub-id><pub-id pub-id-type="pmid">25686104</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobard</surname> <given-names>A</given-names></name><name><surname>Hainault</surname> <given-names>I</given-names></name><name><surname>Ferré</surname> <given-names>P</given-names></name><name><surname>Foufelle</surname> <given-names>F</given-names></name><name><surname>Bossard</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Differential regulation of sterol regulatory element-binding protein 1c transcriptional activity by insulin and liver X receptor during liver development</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1074/jbc.M406522200</pub-id><pub-id pub-id-type="pmid">15509573</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buenrostro</surname> <given-names>JD</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>Greenleaf</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ATAC-seq: a method for assaying chromatin accessibility Genome-Wide</article-title><source>Current Protocols in Molecular Biology</source><volume>109</volume><fpage>21 29 21</fpage><lpage>21 29 29</lpage><pub-id pub-id-type="doi">10.1002/0471142727.mb2129s109</pub-id><pub-id pub-id-type="pmid">25559105</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunn</surname> <given-names>HF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Erythropoietin</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>3</volume><elocation-id>a011619</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a011619</pub-id><pub-id pub-id-type="pmid">23457296</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavard</surname> <given-names>C</given-names></name><name><surname>Colnot</surname> <given-names>S</given-names></name><name><surname>Audard</surname> <given-names>V</given-names></name><name><surname>Benhamouche</surname> <given-names>S</given-names></name><name><surname>Finzi</surname> <given-names>L</given-names></name><name><surname>Torre</surname> <given-names>C</given-names></name><name><surname>Grimber</surname> <given-names>G</given-names></name><name><surname>Godard</surname> <given-names>C</given-names></name><name><surname>Terris</surname> <given-names>B</given-names></name><name><surname>Perret</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology</article-title><source>Future Oncology</source><volume>4</volume><fpage>647</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.2217/14796694.4.5.647</pub-id><pub-id pub-id-type="pmid">18922122</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colnot</surname> <given-names>S</given-names></name><name><surname>Decaens</surname> <given-names>T</given-names></name><name><surname>Niwa-Kawakita</surname> <given-names>M</given-names></name><name><surname>Godard</surname> <given-names>C</given-names></name><name><surname>Hamard</surname> <given-names>G</given-names></name><name><surname>Kahn</surname> <given-names>A</given-names></name><name><surname>Giovannini</surname> <given-names>M</given-names></name><name><surname>Perret</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Liver-targeted disruption of apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas</article-title><source>PNAS</source><volume>101</volume><fpage>17216</fpage><lpage>17221</lpage><pub-id pub-id-type="doi">10.1073/pnas.0404761101</pub-id><pub-id pub-id-type="pmid">15563600</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colnot</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Focusing on beta-catenin activating mutations to refine liver tumor profiling</article-title><source>Hepatology</source><volume>64</volume><fpage>1850</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1002/hep.28761</pub-id><pub-id pub-id-type="pmid">27515244</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corces</surname> <given-names>MR</given-names></name><name><surname>Trevino</surname> <given-names>AE</given-names></name><name><surname>Hamilton</surname> <given-names>EG</given-names></name><name><surname>Greenside</surname> <given-names>PG</given-names></name><name><surname>Sinnott-Armstrong</surname> <given-names>NA</given-names></name><name><surname>Vesuna</surname> <given-names>S</given-names></name><name><surname>Satpathy</surname> <given-names>AT</given-names></name><name><surname>Rubin</surname> <given-names>AJ</given-names></name><name><surname>Montine</surname> <given-names>KS</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Kathiria</surname> <given-names>A</given-names></name><name><surname>Cho</surname> <given-names>SW</given-names></name><name><surname>Mumbach</surname> <given-names>MR</given-names></name><name><surname>Carter</surname> <given-names>AC</given-names></name><name><surname>Kasowski</surname> <given-names>M</given-names></name><name><surname>Orloff</surname> <given-names>LA</given-names></name><name><surname>Risca</surname> <given-names>VI</given-names></name><name><surname>Kundaje</surname> <given-names>A</given-names></name><name><surname>Khavari</surname> <given-names>PA</given-names></name><name><surname>Montine</surname> <given-names>TJ</given-names></name><name><surname>Greenleaf</surname> <given-names>WJ</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues</article-title><source>Nature Methods</source><volume>14</volume><fpage>959</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4396</pub-id><pub-id pub-id-type="pmid">28846090</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de La Coste</surname> <given-names>A</given-names></name><name><surname>Romagnolo</surname> <given-names>B</given-names></name><name><surname>Billuart</surname> <given-names>P</given-names></name><name><surname>Renard</surname> <given-names>CA</given-names></name><name><surname>Buendia</surname> <given-names>MA</given-names></name><name><surname>Soubrane</surname> <given-names>O</given-names></name><name><surname>Fabre</surname> <given-names>M</given-names></name><name><surname>Chelly</surname> <given-names>J</given-names></name><name><surname>Beldjord</surname> <given-names>C</given-names></name><name><surname>Kahn</surname> <given-names>A</given-names></name><name><surname>Perret</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas</article-title><source>PNAS</source><volume>95</volume><fpage>8847</fpage><lpage>8851</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.15.8847</pub-id><pub-id pub-id-type="pmid">9671767</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Serna</surname> <given-names>IL</given-names></name><name><surname>Ohkawa</surname> <given-names>Y</given-names></name><name><surname>Imbalzano</surname> <given-names>AN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Chromatin remodelling in mammalian differentiation: lessons from ATP-dependent remodellers</article-title><source>Nature Reviews Genetics</source><volume>7</volume><fpage>461</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1038/nrg1882</pub-id><pub-id pub-id-type="pmid">16708073</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckey</surname> <given-names>M</given-names></name><name><surname>Kuphal</surname> <given-names>S</given-names></name><name><surname>Straub</surname> <given-names>T</given-names></name><name><surname>Rümmele</surname> <given-names>P</given-names></name><name><surname>Kremmer</surname> <given-names>E</given-names></name><name><surname>Bosserhoff</surname> <given-names>AK</given-names></name><name><surname>Becker</surname> <given-names>PB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Nucleosome remodeler SNF2L suppresses cell proliferation and migration and attenuates wnt signaling</article-title><source>Molecular and Cellular Biology</source><volume>32</volume><fpage>2359</fpage><lpage>2371</lpage><pub-id pub-id-type="doi">10.1128/MCB.06619-11</pub-id><pub-id pub-id-type="pmid">22508985</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>X</given-names></name><name><surname>Tate</surname> <given-names>P</given-names></name><name><surname>Hu</surname> <given-names>P</given-names></name><name><surname>Tjian</surname> <given-names>R</given-names></name><name><surname>Skarnes</surname> <given-names>WC</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a</article-title><source>PNAS</source><volume>105</volume><fpage>6656</fpage><lpage>6661</lpage><pub-id pub-id-type="doi">10.1073/pnas.0801802105</pub-id><pub-id pub-id-type="pmid">18448678</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gougelet</surname> <given-names>A</given-names></name><name><surname>Torre</surname> <given-names>C</given-names></name><name><surname>Veber</surname> <given-names>P</given-names></name><name><surname>Sartor</surname> <given-names>C</given-names></name><name><surname>Bachelot</surname> <given-names>L</given-names></name><name><surname>Denechaud</surname> <given-names>PD</given-names></name><name><surname>Godard</surname> <given-names>C</given-names></name><name><surname>Moldes</surname> <given-names>M</given-names></name><name><surname>Burnol</surname> <given-names>AF</given-names></name><name><surname>Dubuquoy</surname> <given-names>C</given-names></name><name><surname>Terris</surname> <given-names>B</given-names></name><name><surname>Guillonneau</surname> <given-names>F</given-names></name><name><surname>Ye</surname> <given-names>T</given-names></name><name><surname>Schwarz</surname> <given-names>M</given-names></name><name><surname>Braeuning</surname> <given-names>A</given-names></name><name><surname>Perret</surname> <given-names>C</given-names></name><name><surname>Colnot</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>T-cell factor 4 and β-catenin chromatin occupancies pattern zonal liver metabolism in mice</article-title><source>Hepatology</source><volume>59</volume><fpage>2344</fpage><lpage>2357</lpage><pub-id pub-id-type="doi">10.1002/hep.26924</pub-id><pub-id pub-id-type="pmid">24214913</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gougelet</surname> <given-names>A</given-names></name><name><surname>Sartor</surname> <given-names>C</given-names></name><name><surname>Bachelot</surname> <given-names>L</given-names></name><name><surname>Godard</surname> <given-names>C</given-names></name><name><surname>Marchiol</surname> <given-names>C</given-names></name><name><surname>Renault</surname> <given-names>G</given-names></name><name><surname>Tores</surname> <given-names>F</given-names></name><name><surname>Nitschke</surname> <given-names>P</given-names></name><name><surname>Cavard</surname> <given-names>C</given-names></name><name><surname>Terris</surname> <given-names>B</given-names></name><name><surname>Perret</surname> <given-names>C</given-names></name><name><surname>Colnot</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Antitumour activity of an inhibitor of miR-34a in liver Cancer with β-catenin-mutations</article-title><source>Gut</source><volume>65</volume><fpage>1024</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2014-308969</pub-id><pub-id pub-id-type="pmid">25792709</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gougelet</surname> <given-names>A</given-names></name><name><surname>Sartor</surname> <given-names>C</given-names></name><name><surname>Senni</surname> <given-names>N</given-names></name><name><surname>Calderaro</surname> <given-names>J</given-names></name><name><surname>Fartoux</surname> <given-names>L</given-names></name><name><surname>Lequoy</surname> <given-names>M</given-names></name><name><surname>Wendum</surname> <given-names>D</given-names></name><name><surname>Talbot</surname> <given-names>JN</given-names></name><name><surname>Prignon</surname> <given-names>A</given-names></name><name><surname>Chalaye</surname> <given-names>J</given-names></name><name><surname>Imbeaud</surname> <given-names>S</given-names></name><name><surname>Zucman-Rossi</surname> <given-names>J</given-names></name><name><surname>Tordjmann</surname> <given-names>T</given-names></name><name><surname>Godard</surname> <given-names>C</given-names></name><name><surname>Bossard</surname> <given-names>P</given-names></name><name><surname>Rosmorduc</surname> <given-names>O</given-names></name><name><surname>Amaddeo</surname> <given-names>G</given-names></name><name><surname>Colnot</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hepatocellular carcinomas with mutational activation of Beta-Catenin require choline and can be detected by positron emission tomography</article-title><source>Gastroenterology</source><volume>157</volume><fpage>807</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.05.069</pub-id><pub-id pub-id-type="pmid">31194980</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guichard</surname> <given-names>C</given-names></name><name><surname>Amaddeo</surname> <given-names>G</given-names></name><name><surname>Imbeaud</surname> <given-names>S</given-names></name><name><surname>Ladeiro</surname> <given-names>Y</given-names></name><name><surname>Pelletier</surname> <given-names>L</given-names></name><name><surname>Maad</surname> <given-names>IB</given-names></name><name><surname>Calderaro</surname> <given-names>J</given-names></name><name><surname>Bioulac-Sage</surname> <given-names>P</given-names></name><name><surname>Letexier</surname> <given-names>M</given-names></name><name><surname>Degos</surname> <given-names>F</given-names></name><name><surname>Clément</surname> <given-names>B</given-names></name><name><surname>Balabaud</surname> <given-names>C</given-names></name><name><surname>Chevet</surname> <given-names>E</given-names></name><name><surname>Laurent</surname> <given-names>A</given-names></name><name><surname>Couchy</surname> <given-names>G</given-names></name><name><surname>Letouzé</surname> <given-names>E</given-names></name><name><surname>Calvo</surname> <given-names>F</given-names></name><name><surname>Zucman-Rossi</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma</article-title><source>Nature Genetics</source><volume>44</volume><fpage>694</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1038/ng.2256</pub-id><pub-id pub-id-type="pmid">22561517</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidotti</surname> <given-names>JE</given-names></name><name><surname>Brégerie</surname> <given-names>O</given-names></name><name><surname>Robert</surname> <given-names>A</given-names></name><name><surname>Debey</surname> <given-names>P</given-names></name><name><surname>Brechot</surname> <given-names>C</given-names></name><name><surname>Desdouets</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Liver cell polyploidization: a pivotal role for binuclear hepatocytes</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>19095</fpage><lpage>19101</lpage><pub-id pub-id-type="doi">10.1074/jbc.M300982200</pub-id><pub-id pub-id-type="pmid">12626502</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshimoto</surname> <given-names>S</given-names></name><name><surname>Morise</surname> <given-names>Z</given-names></name><name><surname>Suzuki</surname> <given-names>K</given-names></name><name><surname>Tanahashi</surname> <given-names>Y</given-names></name><name><surname>Ikeda</surname> <given-names>M</given-names></name><name><surname>Kagawa</surname> <given-names>T</given-names></name><name><surname>Mizoguchi</surname> <given-names>Y</given-names></name><name><surname>Sugioka</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Hepatocellular carcinoma with extensive peliotic change</article-title><source>Journal of Hepato-Biliary-Pancreatic Surgery</source><volume>16</volume><fpage>566</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1007/s00534-008-0035-9</pub-id><pub-id pub-id-type="pmid">19183829</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>LE</given-names></name><name><surname>Arany</surname> <given-names>Z</given-names></name><name><surname>Livingston</surname> <given-names>DM</given-names></name><name><surname>Bunn</surname> <given-names>HF</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit</article-title><source>Journal of Biological Chemistry</source><volume>271</volume><fpage>32253</fpage><lpage>32259</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.50.32253</pub-id><pub-id pub-id-type="pmid">8943284</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jelkmann</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Erythropoietin after a century of research: younger than ever</article-title><source>European Journal of Haematology</source><volume>78</volume><fpage>183</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0609.2007.00818.x</pub-id><pub-id pub-id-type="pmid">17253966</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadoch</surname> <given-names>C</given-names></name><name><surname>Copeland</surname> <given-names>RA</given-names></name><name><surname>Keilhack</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PRC2 and SWI/SNF chromatin remodeling complexes in health and disease</article-title><source>Biochemistry</source><volume>55</volume><fpage>1600</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.5b01191</pub-id><pub-id pub-id-type="pmid">26836503</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaidi</surname> <given-names>A</given-names></name><name><surname>Williams</surname> <given-names>AC</given-names></name><name><surname>Paraskeva</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia</article-title><source>Nature Cell Biology</source><volume>9</volume><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1038/ncb1534</pub-id><pub-id pub-id-type="pmid">17220880</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Dong</surname> <given-names>Z</given-names></name><name><surname>Hong</surname> <given-names>CS</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Tang</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>P</given-names></name><name><surname>Zhai</surname> <given-names>J</given-names></name><name><surname>Yan</surname> <given-names>H</given-names></name><name><surname>Shen</surname> <given-names>F</given-names></name><name><surname>Zhuang</surname> <given-names>Z</given-names></name><name><surname>Wen</surname> <given-names>W</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Erythrocytosis in hepatocellular carcinoma portends poor prognosis by respiratory dysfunction secondary to mitochondrial DNA mutations</article-title><source>Hepatology</source><volume>65</volume><fpage>134</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1002/hep.28889</pub-id><pub-id pub-id-type="pmid">27774607</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimáková</surname> <given-names>P</given-names></name><name><surname>Solár</surname> <given-names>P</given-names></name><name><surname>Solárová</surname> <given-names>Z</given-names></name><name><surname>Komel</surname> <given-names>R</given-names></name><name><surname>Debeljak</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Erythropoietin and its angiogenic activity</article-title><source>International Journal of Molecular Sciences</source><volume>18</volume><elocation-id>1519</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18071519</pub-id><pub-id pub-id-type="pmid">28703764</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kular</surname> <given-names>D</given-names></name><name><surname>Macdougall</surname> <given-names>IC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HIF stabilizers in the management of renal Anemia: from bench to bedside to pediatrics</article-title><source>Pediatric Nephrology</source><volume>34</volume><fpage>365</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1007/s00467-017-3849-3</pub-id><pub-id pub-id-type="pmid">29569190</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacombe</surname> <given-names>C</given-names></name><name><surname>Da Silva</surname> <given-names>JL</given-names></name><name><surname>Bruneval</surname> <given-names>P</given-names></name><name><surname>Fournier</surname> <given-names>JG</given-names></name><name><surname>Wendling</surname> <given-names>F</given-names></name><name><surname>Casadevall</surname> <given-names>N</given-names></name><name><surname>Camilleri</surname> <given-names>JP</given-names></name><name><surname>Bariety</surname> <given-names>J</given-names></name><name><surname>Varet</surname> <given-names>B</given-names></name><name><surname>Tambourin</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney</article-title><source>Journal of Clinical Investigation</source><volume>81</volume><fpage>620</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1172/JCI113363</pub-id><pub-id pub-id-type="pmid">3339134</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastrogiannaki</surname> <given-names>M</given-names></name><name><surname>Matak</surname> <given-names>P</given-names></name><name><surname>Keith</surname> <given-names>B</given-names></name><name><surname>Simon</surname> <given-names>MC</given-names></name><name><surname>Vaulont</surname> <given-names>S</given-names></name><name><surname>Peyssonnaux</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice</article-title><source>Journal of Clinical Investigation</source><volume>119</volume><fpage>1159</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1172/JCI38499</pub-id><pub-id pub-id-type="pmid">19352007</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastrogiannaki</surname> <given-names>M</given-names></name><name><surname>Matak</surname> <given-names>P</given-names></name><name><surname>Mathieu</surname> <given-names>JR</given-names></name><name><surname>Delga</surname> <given-names>S</given-names></name><name><surname>Mayeux</surname> <given-names>P</given-names></name><name><surname>Vaulont</surname> <given-names>S</given-names></name><name><surname>Peyssonnaux</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis</article-title><source>Haematologica</source><volume>97</volume><fpage>827</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.3324/haematol.2011.056119</pub-id><pub-id pub-id-type="pmid">22207682</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathur</surname> <given-names>R</given-names></name><name><surname>Alver</surname> <given-names>BH</given-names></name><name><surname>San Roman</surname> <given-names>AK</given-names></name><name><surname>Wilson</surname> <given-names>BG</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Agoston</surname> <given-names>AT</given-names></name><name><surname>Park</surname> <given-names>PJ</given-names></name><name><surname>Shivdasani</surname> <given-names>RA</given-names></name><name><surname>Roberts</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ARID1A loss impairs enhancer-mediated gene regulation and drives Colon cancer in mice</article-title><source>Nature Genetics</source><volume>49</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1038/ng.3744</pub-id><pub-id pub-id-type="pmid">27941798</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname> <given-names>M</given-names></name><name><surname>Yamazaki</surname> <given-names>O</given-names></name><name><surname>Horii</surname> <given-names>K</given-names></name><name><surname>Higaki</surname> <given-names>I</given-names></name><name><surname>Kawai</surname> <given-names>S</given-names></name><name><surname>Mikami</surname> <given-names>S</given-names></name><name><surname>Higashino</surname> <given-names>M</given-names></name><name><surname>Oka</surname> <given-names>H</given-names></name><name><surname>Nakai</surname> <given-names>T</given-names></name><name><surname>Inoue</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma</article-title><source>Journal of Surgical Oncology</source><volume>75</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/1096-9098(200011)75:3&lt;197::AID-JSO8&gt;3.0.CO;2-I</pub-id><pub-id pub-id-type="pmid">11088052</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minamishima</surname> <given-names>YA</given-names></name><name><surname>Kaelin</surname> <given-names>WG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Reactivation of hepatic EPO synthesis in mice after PHD loss</article-title><source>Science</source><volume>329</volume><elocation-id>407</elocation-id><pub-id pub-id-type="doi">10.1126/science.1192811</pub-id><pub-id pub-id-type="pmid">20651146</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monga</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>β-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis</article-title><source>Gastroenterology</source><volume>148</volume><fpage>1294</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.02.056</pub-id><pub-id pub-id-type="pmid">25747274</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosimann</surname> <given-names>C</given-names></name><name><surname>Hausmann</surname> <given-names>G</given-names></name><name><surname>Basler</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Beta-catenin hits chromatin: regulation of wnt target gene activation</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>10</volume><fpage>276</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1038/nrm2654</pub-id><pub-id pub-id-type="pmid">19305417</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagl</surname> <given-names>NG</given-names></name><name><surname>Patsialou</surname> <given-names>A</given-names></name><name><surname>Haines</surname> <given-names>DS</given-names></name><name><surname>Dallas</surname> <given-names>PB</given-names></name><name><surname>Beck</surname> <given-names>GR</given-names></name><name><surname>Moran</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest</article-title><source>Cancer Research</source><volume>65</volume><fpage>9236</fpage><lpage>9244</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1225</pub-id><pub-id pub-id-type="pmid">16230384</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogueira-Pedro</surname> <given-names>A</given-names></name><name><surname>dos Santos</surname> <given-names>GG</given-names></name><name><surname>Oliveira</surname> <given-names>DC</given-names></name><name><surname>Hastreiter</surname> <given-names>AA</given-names></name><name><surname>Fock</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Erythropoiesis in vertebrates: from ontogeny to clinical relevance</article-title><source>Frontiers in Bioscience : A Journal and Virtual Library</source><volume>8</volume><fpage>100</fpage><lpage>112</lpage></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname> <given-names>JM</given-names></name><name><surname>Harandi</surname> <given-names>OF</given-names></name><name><surname>Porayette</surname> <given-names>P</given-names></name><name><surname>Hegde</surname> <given-names>S</given-names></name><name><surname>Kannan</surname> <given-names>AK</given-names></name><name><surname>Paulson</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Maintenance of the BMP4-dependent stress erythropoiesis pathway in the murine spleen requires hedgehog signaling</article-title><source>Blood</source><volume>113</volume><fpage>911</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-03-147892</pub-id><pub-id pub-id-type="pmid">18927434</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planas-Paz</surname> <given-names>L</given-names></name><name><surname>Orsini</surname> <given-names>V</given-names></name><name><surname>Boulter</surname> <given-names>L</given-names></name><name><surname>Calabrese</surname> <given-names>D</given-names></name><name><surname>Pikiolek</surname> <given-names>M</given-names></name><name><surname>Nigsch</surname> <given-names>F</given-names></name><name><surname>Xie</surname> <given-names>Y</given-names></name><name><surname>Roma</surname> <given-names>G</given-names></name><name><surname>Donovan</surname> <given-names>A</given-names></name><name><surname>Marti</surname> <given-names>P</given-names></name><name><surname>Beckmann</surname> <given-names>N</given-names></name><name><surname>Dill</surname> <given-names>MT</given-names></name><name><surname>Carbone</surname> <given-names>W</given-names></name><name><surname>Bergling</surname> <given-names>S</given-names></name><name><surname>Isken</surname> <given-names>A</given-names></name><name><surname>Mueller</surname> <given-names>M</given-names></name><name><surname>Kinzel</surname> <given-names>B</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Mao</surname> <given-names>X</given-names></name><name><surname>Nicholson</surname> <given-names>TB</given-names></name><name><surname>Zamponi</surname> <given-names>R</given-names></name><name><surname>Capodieci</surname> <given-names>P</given-names></name><name><surname>Valdez</surname> <given-names>R</given-names></name><name><surname>Rivera</surname> <given-names>D</given-names></name><name><surname>Loew</surname> <given-names>A</given-names></name><name><surname>Ukomadu</surname> <given-names>C</given-names></name><name><surname>Terracciano</surname> <given-names>LM</given-names></name><name><surname>Bouwmeester</surname> <given-names>T</given-names></name><name><surname>Cong</surname> <given-names>F</given-names></name><name><surname>Heim</surname> <given-names>MH</given-names></name><name><surname>Forbes</surname> <given-names>SJ</given-names></name><name><surname>Ruffner</surname> <given-names>H</given-names></name><name><surname>Tchorz</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size</article-title><source>Nature Cell Biology</source><volume>18</volume><fpage>467</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1038/ncb3337</pub-id><pub-id pub-id-type="pmid">27088858</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebouissou</surname> <given-names>S</given-names></name><name><surname>Franconi</surname> <given-names>A</given-names></name><name><surname>Calderaro</surname> <given-names>J</given-names></name><name><surname>Letouzé</surname> <given-names>E</given-names></name><name><surname>Imbeaud</surname> <given-names>S</given-names></name><name><surname>Pilati</surname> <given-names>C</given-names></name><name><surname>Nault</surname> <given-names>JC</given-names></name><name><surname>Couchy</surname> <given-names>G</given-names></name><name><surname>Laurent</surname> <given-names>A</given-names></name><name><surname>Balabaud</surname> <given-names>C</given-names></name><name><surname>Bioulac-Sage</surname> <given-names>P</given-names></name><name><surname>Zucman-Rossi</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression</article-title><source>Hepatology</source><volume>64</volume><fpage>2047</fpage><lpage>2061</lpage><pub-id pub-id-type="doi">10.1002/hep.28638</pub-id><pub-id pub-id-type="pmid">27177928</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruschitzka</surname> <given-names>FT</given-names></name><name><surname>Wenger</surname> <given-names>RH</given-names></name><name><surname>Stallmach</surname> <given-names>T</given-names></name><name><surname>Quaschning</surname> <given-names>T</given-names></name><name><surname>de Wit</surname> <given-names>C</given-names></name><name><surname>Wagner</surname> <given-names>K</given-names></name><name><surname>Labugger</surname> <given-names>R</given-names></name><name><surname>Kelm</surname> <given-names>M</given-names></name><name><surname>Noll</surname> <given-names>G</given-names></name><name><surname>Rülicke</surname> <given-names>T</given-names></name><name><surname>Shaw</surname> <given-names>S</given-names></name><name><surname>Lindberg</surname> <given-names>RL</given-names></name><name><surname>Rodenwaldt</surname> <given-names>B</given-names></name><name><surname>Lutz</surname> <given-names>H</given-names></name><name><surname>Bauer</surname> <given-names>C</given-names></name><name><surname>Lüscher</surname> <given-names>TF</given-names></name><name><surname>Gassmann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin</article-title><source>PNAS</source><volume>97</volume><fpage>11609</fpage><lpage>11613</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.21.11609</pub-id><pub-id pub-id-type="pmid">11027359</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname> <given-names>GL</given-names></name><name><surname>Koury</surname> <given-names>ST</given-names></name><name><surname>Nejfelt</surname> <given-names>MK</given-names></name><name><surname>Gearhart</surname> <given-names>JD</given-names></name><name><surname>Antonarakis</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice</article-title><source>PNAS</source><volume>88</volume><fpage>8725</fpage><lpage>8729</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.19.8725</pub-id><pub-id pub-id-type="pmid">1924331</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sena</surname> <given-names>JA</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Hu</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>BRG1 and BRM chromatin-remodeling complexes regulate the hypoxia response by acting as coactivators for a subset of hypoxia-inducible transcription factor target genes</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>3849</fpage><lpage>3863</lpage><pub-id pub-id-type="doi">10.1128/MCB.00731-13</pub-id><pub-id pub-id-type="pmid">23897427</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senni</surname> <given-names>N</given-names></name><name><surname>Savall</surname> <given-names>M</given-names></name><name><surname>Cabrerizo Granados</surname> <given-names>D</given-names></name><name><surname>Alves-Guerra</surname> <given-names>MC</given-names></name><name><surname>Sartor</surname> <given-names>C</given-names></name><name><surname>Lagoutte</surname> <given-names>I</given-names></name><name><surname>Gougelet</surname> <given-names>A</given-names></name><name><surname>Terris</surname> <given-names>B</given-names></name><name><surname>Gilgenkrantz</surname> <given-names>H</given-names></name><name><surname>Perret</surname> <given-names>C</given-names></name><name><surname>Colnot</surname> <given-names>S</given-names></name><name><surname>Bossard</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>β-catenin-activated hepatocellular carcinomas are addicted to fatty acids</article-title><source>Gut</source><volume>68</volume><fpage>322</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2017-315448</pub-id><pub-id pub-id-type="pmid">29650531</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snipstad</surname> <given-names>S</given-names></name><name><surname>Berg</surname> <given-names>S</given-names></name><name><surname>Mørch</surname> <given-names>Ý</given-names></name><name><surname>Bjørkøy</surname> <given-names>A</given-names></name><name><surname>Sulheim</surname> <given-names>E</given-names></name><name><surname>Hansen</surname> <given-names>R</given-names></name><name><surname>Grimstad</surname> <given-names>I</given-names></name><name><surname>van Wamel</surname> <given-names>A</given-names></name><name><surname>Maaland</surname> <given-names>AF</given-names></name><name><surname>Torp</surname> <given-names>SH</given-names></name><name><surname>Davies</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ultrasound improves the delivery and therapeutic effect of Nanoparticle-Stabilized Microbubbles in Breast Cancer Xenografts</article-title><source>Ultrasound in Medicine &amp; Biology</source><volume>43</volume><fpage>2651</fpage><lpage>2669</lpage><pub-id pub-id-type="doi">10.1016/j.ultrasmedbio.2017.06.029</pub-id><pub-id pub-id-type="pmid">28781149</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>H</given-names></name><name><surname>Spichiger-Haeusermann</surname> <given-names>C</given-names></name><name><surname>Basler</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The ISWI-containing NURF complex regulates the output of the canonical wingless pathway</article-title><source>EMBO Reports</source><volume>10</volume><fpage>1140</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1038/embor.2009.157</pub-id><pub-id pub-id-type="pmid">19713963</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Chuang</surname> <given-names>JC</given-names></name><name><surname>Kanchwala</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Celen</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Liang</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Maples</surname> <given-names>T</given-names></name><name><surname>Nguyen</surname> <given-names>LH</given-names></name><name><surname>Wang</surname> <given-names>SC</given-names></name><name><surname>Signer</surname> <given-names>RA</given-names></name><name><surname>Sorouri</surname> <given-names>M</given-names></name><name><surname>Nassour</surname> <given-names>I</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>M</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Kuo</surname> <given-names>YC</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Xing</surname> <given-names>C</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Suppression of the SWI/SNF component Arid1a promotes mammalian regeneration</article-title><source>Cell Stem Cell</source><volume>18</volume><fpage>456</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.03.001</pub-id><pub-id pub-id-type="pmid">27044474</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>SC</given-names></name><name><surname>Wei</surname> <given-names>Y</given-names></name><name><surname>Luo</surname> <given-names>X</given-names></name><name><surname>Jia</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Gopal</surname> <given-names>P</given-names></name><name><surname>Zhu</surname> <given-names>M</given-names></name><name><surname>Nassour</surname> <given-names>I</given-names></name><name><surname>Chuang</surname> <given-names>JC</given-names></name><name><surname>Maples</surname> <given-names>T</given-names></name><name><surname>Celen</surname> <given-names>C</given-names></name><name><surname>Nguyen</surname> <given-names>LH</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Fu</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Hui</surname> <given-names>L</given-names></name><name><surname>Tian</surname> <given-names>F</given-names></name><name><surname>Ji</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Sorouri</surname> <given-names>M</given-names></name><name><surname>Hwang</surname> <given-names>TH</given-names></name><name><surname>Letzig</surname> <given-names>L</given-names></name><name><surname>James</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Yopp</surname> <given-names>AC</given-names></name><name><surname>Singal</surname> <given-names>AG</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Arid1a has Context-Dependent oncogenic and tumor suppressor functions in liver Cancer</article-title><source>Cancer Cell</source><volume>33</volume><fpage>151</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.12.011</pub-id><pub-id pub-id-type="pmid">29316428</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname> <given-names>N</given-names></name><name><surname>Obara</surname> <given-names>N</given-names></name><name><surname>Pan</surname> <given-names>X</given-names></name><name><surname>Watanabe</surname> <given-names>M</given-names></name><name><surname>Jishage</surname> <given-names>K</given-names></name><name><surname>Minegishi</surname> <given-names>N</given-names></name><name><surname>Yamamoto</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Specific contribution of the erythropoietin gene 3' enhancer to hepatic erythropoiesis after late embryonic stages</article-title><source>Molecular and Cellular Biology</source><volume>31</volume><fpage>3896</fpage><lpage>3905</lpage><pub-id pub-id-type="doi">10.1128/MCB.05463-11</pub-id><pub-id pub-id-type="pmid">21746884</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Erythropoietin gene expression: developmental-stage specificity, cell-type specificity, and hypoxia inducibility</article-title><source>The Tohoku Journal of Experimental Medicine</source><volume>235</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1620/tjem.235.233</pub-id><pub-id pub-id-type="pmid">25786542</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname> <given-names>K</given-names></name><name><surname>Aguila</surname> <given-names>HL</given-names></name><name><surname>Parikh</surname> <given-names>NS</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Lamothe</surname> <given-names>K</given-names></name><name><surname>Duan</surname> <given-names>LJ</given-names></name><name><surname>Takeda</surname> <given-names>H</given-names></name><name><surname>Lee</surname> <given-names>FS</given-names></name><name><surname>Fong</surname> <given-names>GH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins</article-title><source>Blood</source><volume>111</volume><fpage>3229</fpage><lpage>3235</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-09-114561</pub-id><pub-id pub-id-type="pmid">18056838</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannour-Louet</surname> <given-names>M</given-names></name><name><surname>Porteu</surname> <given-names>A</given-names></name><name><surname>Vaulont</surname> <given-names>S</given-names></name><name><surname>Kahn</surname> <given-names>A</given-names></name><name><surname>Vasseur-Cognet</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A tamoxifen-inducible chimeric cre recombinase specifically effective in the fetal and adult mouse liver</article-title><source>Hepatology</source><volume>35</volume><fpage>1072</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1053/jhep.2002.33164</pub-id><pub-id pub-id-type="pmid">11981757</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname> <given-names>C</given-names></name><name><surname>Benhamouche</surname> <given-names>S</given-names></name><name><surname>Mitchell</surname> <given-names>C</given-names></name><name><surname>Godard</surname> <given-names>C</given-names></name><name><surname>Veber</surname> <given-names>P</given-names></name><name><surname>Letourneur</surname> <given-names>F</given-names></name><name><surname>Cagnard</surname> <given-names>N</given-names></name><name><surname>Jacques</surname> <given-names>S</given-names></name><name><surname>Finzi</surname> <given-names>L</given-names></name><name><surname>Perret</surname> <given-names>C</given-names></name><name><surname>Colnot</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The transforming growth factor-α and cyclin D1 genes are direct targets of β-catenin signaling in hepatocyte proliferation</article-title><source>Journal of Hepatology</source><volume>55</volume><fpage>86</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.10.021</pub-id><pub-id pub-id-type="pmid">21145869</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname> <given-names>LA</given-names></name><name><surname>Siegel</surname> <given-names>RL</given-names></name><name><surname>Ward</surname> <given-names>EM</given-names></name><name><surname>Jemal</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Global Cancer incidence and mortality rates and trends--an update</article-title><source>Cancer Epidemiology Biomarkers &amp; Prevention</source><volume>25</volume><fpage>16</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-15-0578</pub-id><pub-id pub-id-type="pmid">26667886</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchiya</surname> <given-names>A</given-names></name><name><surname>Kubota</surname> <given-names>T</given-names></name><name><surname>Takizawa</surname> <given-names>K</given-names></name><name><surname>Yamada</surname> <given-names>K</given-names></name><name><surname>Wakai</surname> <given-names>T</given-names></name><name><surname>Matsuda</surname> <given-names>Y</given-names></name><name><surname>Honma</surname> <given-names>T</given-names></name><name><surname>Watanabe</surname> <given-names>M</given-names></name><name><surname>Shirai</surname> <given-names>Y</given-names></name><name><surname>Maruyama</surname> <given-names>H</given-names></name><name><surname>Nomoto</surname> <given-names>M</given-names></name><name><surname>Aoyagi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Successful treatment in a case of massive hepatocellular carcinoma with paraneoplastic syndrome</article-title><source>Case Reports in Gastroenterology</source><volume>3</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1159/000213480</pub-id><pub-id pub-id-type="pmid">20651974</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valla</surname> <given-names>DC</given-names></name><name><surname>Cazals-Hatem</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts</article-title><source>Virchows Archiv</source><volume>473</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s00428-018-2331-3</pub-id><pub-id pub-id-type="pmid">29572606</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vik</surname> <given-names>A</given-names></name><name><surname>Cui</surname> <given-names>G</given-names></name><name><surname>Isaksen</surname> <given-names>V</given-names></name><name><surname>Wik</surname> <given-names>T</given-names></name><name><surname>Hansen</surname> <given-names>JB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Erythropoietin production by a hepatic adenoma in a patient with severe erythrocytosis</article-title><source>Acta Haematologica</source><volume>121</volume><fpage>52</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1159/000210556</pub-id><pub-id pub-id-type="pmid">19339771</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name><name><surname>Beischlag</surname> <given-names>TV</given-names></name><name><surname>Muchardt</surname> <given-names>C</given-names></name><name><surname>Yaniv</surname> <given-names>M</given-names></name><name><surname>Hankinson</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Roles of brahma and brahma/SWI2-related gene 1 in hypoxic induction of the erythropoietin gene</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>46733</fpage><lpage>46741</lpage><pub-id pub-id-type="doi">10.1074/jbc.M409002200</pub-id><pub-id pub-id-type="pmid">15347669</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidemann</surname> <given-names>A</given-names></name><name><surname>Johnson</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Nonrenal regulation of EPO synthesis</article-title><source>Kidney International</source><volume>75</volume><fpage>682</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1038/ki.2008.687</pub-id><pub-id pub-id-type="pmid">19165176</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>HB</given-names></name><name><surname>Wang</surname> <given-names>XF</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Tang</surname> <given-names>ZQ</given-names></name><name><surname>Jiang</surname> <given-names>YH</given-names></name><name><surname>Fan</surname> <given-names>HZ</given-names></name><name><surname>Sun</surname> <given-names>YH</given-names></name><name><surname>Yang</surname> <given-names>PY</given-names></name><name><surname>Liu</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reduced expression of the chromatin remodeling gene ARID1A enhances gastric Cancer cell migration and invasion via downregulation of E-cadherin transcription</article-title><source>Carcinogenesis</source><volume>35</volume><fpage>867</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgt398</pub-id><pub-id pub-id-type="pmid">24293408</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaret</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>From endoderm to liver bud: paradigms of cell type specification and tissue morphogenesis</article-title><source>Current Topics in Developmental Biology</source><volume>117</volume><fpage>647</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1016/bs.ctdb.2015.12.015</pub-id><pub-id pub-id-type="pmid">26970006</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname> <given-names>Y</given-names></name><name><surname>Kuick</surname> <given-names>R</given-names></name><name><surname>Tipton</surname> <given-names>C</given-names></name><name><surname>Wu</surname> <given-names>R</given-names></name><name><surname>Sessine</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Baker</surname> <given-names>SJ</given-names></name><name><surname>Fearon</surname> <given-names>ER</given-names></name><name><surname>Cho</surname> <given-names>KR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Arid1a inactivation in an apc- and Pten-defective mouse ovarian Cancer model enhances epithelial differentiation and prolongs survival</article-title><source>The Journal of Pathology</source><volume>238</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1002/path.4599</pub-id><pub-id pub-id-type="pmid">26279473</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.53550.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Davidson</surname><given-names>Irwin</given-names></name><role>Reviewing Editor</role><aff><institution>Institut de Génétique et de Biologie Moléculaire et Cellulaire</institution><country>France</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Davidson</surname><given-names>Irwin</given-names> </name><role>Reviewer</role><aff><institution>Institut de Génétique et de Biologie Moléculaire et Cellulaire</institution><country>France</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Bird</surname><given-names>Tom</given-names> </name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Riou et al. describe how the <italic>Arid1a</italic> subunit of the SWI/SNF chromatin remodelling complex cooperates with activated Wnt signalling to induce re-expression of the erythropoeitin (EPO) hormone in liver hepatocytes. The overexpressed EPO induces increased red blood cell production in the spleen leading to erythrocytosis and local angiogenesis in the liver. <italic>Arid1a</italic> regulates binding of the TCF4-β catenin complex to an Hnf4a response element in the 3' enhancer of the EPO gene that to promote its expression upon activation of Wnt signalling.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;ARID1A loss in adult hepatocytes unleashes β-catenin-mediated erythropoietin transcription&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, including Irwin Davidson as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Didier Stainier as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Tom Bird (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This paper describes a potential mechanism by which the SWI/SNF subunit <italic>Arid1a</italic> cooperates with activated Wnt signaling to induce re-expression of the EPO hormone in liver hepatocytes. This study provides new data on how Wnt signaling can regulate EPO expression and on an interplay between <italic>Arid1a</italic>, chromatin accessibility and Wnt signaling. While the reviewers found this study to be of significant interest, a number of major issues should be addressed in a revised version of the paper.</p><p>Essential revisions:</p><p>1) In Figure 9, the authors summarize their data and proposes a model for how Arid1A regulates TCF4-b-cat activation of the EPO gene. It would be essential to perform ATAC-seq or at least ATAC-qPCR to demonstrate changes in accessibility of the EPO regulatory element under the different conditions. The model proposes that in wild-type conditions and in APC-mutant conditions the SWI/SNF complex is bound at the regulatory element and that it is released under conditions where <italic>Arid1a</italic> is deleted. This model can be easily tested using antibodies that ChIP components of the SWI/SNF complex. The best would be <italic>Arid1a</italic> in combination with other subunits, but if there are no ChIP-grade <italic>Arid1a</italic> antibodies, the authors could at least determine whether SWI/SNF is present under these conditions and released upon <italic>Arid1a</italic> inactivation. One could also imagine other models where SWI/SNF without <italic>Arid1a</italic> is also bound when the element is activated, but with different functional outcome in the presence or absence of Ardi1a. Additional ATAC or ChIP experiments could easily discriminate these possibilities. It is essential that the authors address these issues.</p><p>2) The data for physiologically relevant production of Epo by hepatocytes in the model must be more convincingly shown. The absence of systemic/hepatic and renal hypoxia should be more robustly demonstrated. The production of physiologically meaningful Epo by hepatocytes should be shown. It is proposed that the 2-4-fold increase in transcript/reporter observed in cell lines is responsible for the 2-3-fold increase in systemic Epo; most of which is derived from kidney physiologically. Comparing kidney as positive control at transcript level would be helpful as well as measurement at protein level in liver and kidney. The authors should quantify and compare hepatic and kidney EPO expression in the different genetic backgrounds. This could be done by both qRT-PCR and by RNA-fish/RNAscope on sections from both kidney and liver. It is essential the authors quantify relative EPO expression in both organs.</p><p>3) The authors should address if the observed peliosis is related to sinusoidal obstruction related to the polycythaemia. If this is the case then this would be consistent with the splenomegaly – due to portal hypertension. Is there flow in the peliotic regions on ultrasound? An alternative explanation for the results in this paper would be that a combination of Arid1/APC deletion results in sinusoidal constriction/obstruction with pooling/extravasation of blood. This constriction would then lead to portal hypertension and increased Epo release by the kidney resulting in polycythaemia and peliosis. This seems a potential explanation and is not refuted by the data presented.</p><p>4) Peliosis and HCC have been described together in HCC but this is not referenced e.g. doi: 10.1007/s00534-008-0035-9. Furthermore, interrogation of publicly available datasets (e.g. TCGA) may add strength to the proposition that Wnt pathway mutations in combination with Arid1A give rise to Epo production within the liver tumour.</p><p>5) A statement regarding the cause of death in APC/Arid1 animals should be provided to support the authors claim that this is secondary to peliosis. This is not normally itself a fatal disorder, so why do the authors propose it is in this model? Similarly, is there correlation between the ultrasound findings and endpoint liver examination at post mortem?</p><p>6) In line with general recommendations in mouse work it would be important to show that the key findings are present in both male and female model systems.</p><p>7) Additional replicates are necessary to show absence of effects of HIF targets. There do appear to be differences in at least some of these and it is likely that n=4 will be insufficient to demonstrate equivalence.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;ARID1A loss in adult hepatocytes activates β-catenin-mediated erythropoietin transcription&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Didier Stainier (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:</p><p>The manuscript of Riou et al. has been substantially modified and reorganised. The authors have performed the majority of the essential revisions, in particular the RNAscope analyses of EPO expression in the wild-type and mutant livers and kidneys. The only experiment that could not be performed was the analyses of the phenotype of the female mice that is likely to take a much longer time due to the COVID crisis that restricted access and breeding in the animal facility.</p><p>While the manuscript is very much improved, several issues still require attention and should be addressed before final acceptance.</p><p>1) In the rebuttal letter and in the revised text, the authors describe the EPO expression seen by RNAscope experiments as “bursty” or “stochastic”. While this may be the case, it is not fully justified, nor necessary to explain the phenotype to describe EPO expression in this way. The text should be modified.</p><p>2) The ATAC-qPCR experiments did not reveal increased chromatin accessibility upon <italic>Arid1a</italic> inactivation, in fact, chromatin accessibility appeared to decrease compared to Apc inactivation alone. It appears that only a single primer set was used that overlaps with the TCF binding site. From this limited analysis, it is difficult to assess exact nucleosome positioning and how it may be affected by <italic>Arid1a</italic> loss. It would have been more appropriate to test several amplicons spanning the enhancer. This would have perhaps better revealed how <italic>Arid1a</italic> loss affects nucleosome positioning and accessibility.</p><p>3) Last but not least, the quality of the English in the revised version is very poor leading to lack of precision and making the text difficult to follow. A thorough revision of the text by a native speaker is essential.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.53550.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) In Figure 9, the authors summarize their data and proposes a model for how Arid1A regulates TCF4-b-cat activation of the EPO gene. It would be essential to perform ATAC-seq or at least ATAC-qPCR to demonstrate changes in accessibility of the EPO regulatory element under the different conditions. The model proposes that in wild-type conditions and in APC-mutant conditions the SWI/SNF complex is bound at the regulatory element and that it is released under conditions where Arid1a is deleted. This model can be easily tested using antibodies that ChIP components of the SWI/SNF complex. The best would be Arid1a in combination with other subunits, but if there are no ChIP-grade Arid1a antibodies, the authors could at least determine whether SWI/SNF is present under these conditions and released upon Arid1a inactivation. One could also imagine other models where SWI/SNF without Arid1a is also bound when the element is activated, but with different functional outcome in the presence or absence of Ardi1a. Additional ATAC or ChIP experiments could easily discriminate these possibilities. It is essential that the authors address these issues.</p></disp-quote><p>We agreed with this essential requirement. We had tried ChIP-qPCR experiments using antibodies against Arid1a or against Brg1. But primary mouse hepatocytes are difficult to study by ChIP and this previously took us time to implement ChIP against Tcf4 and/or β-catenin (see Gougelet et al., 2014). Consequently, we got no convincing data using these antibodies. We thus undertook ATAC-qPCR experiments using OMNI-ATAC recently described technique, which works on frozen liver tissue. We clearly found that chromatin accessibility increased after β-catenin activation on GS, Axin2 and Epo enhancer. But surprisingly, this was not the case when Arid1a gene is inactivated. This goes well with the fact that Arid1a is a facultative component of BAF SWI/SNF chromatin complex, which can be replaced by Arid1b. This has been added in Figure 8F, leading to a modified model of transcription of Epo shown in Figure 9. This is described in the text: “Tcf4 bound in vivo to the <italic>Epo</italic> enhancer and such binding was slightly higher in [<italic>Apc</italic>]<sup>ko-TOTAL</sup> and much higher in [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> hepatocytes than in controls (Figure 8E). After a single β-catenin activation process, the H3K27me3 repressive mark slightly decreased and chromatin was more accessible (Figure 8F). In contrast, the loss of Arid1a strongly decreased H3K27Me3 repressive mark without modifying chromatin access. In [<italic>Apc-Arid1a</italic>]<sup>ko-TOTAL</sup> hepatocytes, a H3K27Ac active histone mark was induced while chromatin accessibility was lower.” This is also discussed: “For Epo enhancer, the increased binding of Tcf4/β-catenin complex to the Hnf4-RE is dependent on <italic>Arid1a</italic>, whose loss decreases H3K27me3 repressive mark. That could be due to the complex existing balance between the Polycomb complex PRC2 (catalyzing the addition of methyl groups to histone H3 at lysine 27) and the SWI/SNF complex (Kadoch, Copeland and Keilhack, 2016). Accordingly, the inhibition of the Polycomb EZH2 subunit is synthetically lethal in ARID1A-mutated tumors (Bitler et al., 2015; Allredge and Eskander, 2017). Therefore, Arid1a and Polycomb complex could act in concert to modulate liver expression of the <italic>Epo</italic> gene”.</p><disp-quote content-type="editor-comment"><p>2) The data for physiologically relevant production of Epo by hepatocytes in the model must be more convincingly shown. The absence of systemic/hepatic and renal hypoxia should be more robustly demonstrated. The production of physiologically meaningful Epo by hepatocytes should be shown. It is proposed that the 2-4-fold increase in transcript/reporter observed in cell lines is responsible for the 2-3-fold increase in systemic Epo; most of which is derived from kidney physiologically. Comparing kidney as positive control at transcript level would be helpful as well as measurement at protein level in liver and kidney. The authors should quantify and compare hepatic and kidney EPO expression in the different genetic backgrounds. This could be done by both qRT-PCR and by RNA-fish/RNAscope on sections from both kidney and liver. It is essential the authors quantify relative EPO expression in both organs.</p></disp-quote><p>Here again, the reviewers indicated some useful experiments to perform. We first assessed Epo mRNA expression by qPCR in the transgenic kidneys, and showed that there is no increase in renal Epo expression after either focal (new Figure 2E) or panlobular (new Figure 5D) Apc/Arid inactivations. In this latter case, there is rather a slight decrease of renal Epo after hepatic Apc/Arid knock-out. This clearly showed that the systemic impact of Epo is due to hepatic de novo transcription. We also performed. In this context, measuring renal hypoxia was not of interest. We focused on hepatic localization of Epo transcripts. After some attempts to perform classical in situ hybridizations, even if we are expert in mRNA ISH in the liver (Benhamouche et al., 2006), they failed when assessing Epo transcripts. We thus performed highly sensitive RNAScope experiments, and as expected we showed: (1) that Epo mRNA are only detectable in rare renal interstitial cells of normal kidney; (2) that no Epo is detected in normal livers (Figure 6—figure supplement 1). In transgenic livers, we were able to detect Epo transcripts only in rare Axin2-expressing (and thus β-catenin-activated) hepatocytes of Apc/Arid knock-out livers. This exciting experiment clearly underlines a stochastic and bursty transcription of Epo as described previously for several hepatic mRNAs by Itzkovitz’ team using single-RNA ISH (Halpern, Nature 2015).</p><disp-quote content-type="editor-comment"><p>3) The authors should address if the observed peliosis is related to sinusoidal obstruction related to the polycythaemia. If this is the case then this would be consistent with the splenomegaly – due to portal hypertension. Is there flow in the peliotic regions on ultrasound? An alternative explanation for the results in this paper would be that a combination of Arid1/APC deletion results in sinusoidal constriction/obstruction with pooling/extravasation of blood. This constriction would then lead to portal hypertension and increased Epo release by the kidney resulting in polycythaemia and peliosis. This seems a potential explanation and is not refuted by the data presented.</p></disp-quote><p>In keeping with this hypothesis, we performed dynamic ultrasound using microbubble administration and an example is shown in Figure 1—figure supplement 2. It clearly showed that there is a decrease in hepatic vascular perfusion within echogenic areas enriched in Apc/Arid inactivated hepatocytes. However, no modification in kidney Epo expression was seen, showing that the primary defect resulting in polycythaemia and peliosis is a hepatic one.</p><disp-quote content-type="editor-comment"><p>4) Peliosis and HCC have been described together in HCC but this is not referenced e.g. doi: 10.1007/s00534-008-0035-9. Furthermore, interrogation of publicly available datasets (e.g. TCGA) may add strength to the proposition that Wnt pathway mutations in combination with Arid1A give rise to Epo production within the liver tumour.</p></disp-quote><p>Thank you for the reference about peliosis and HCC, added in the Discussion paragraph eight. We have interrogated TCGA dataset as legitimately proposed. We could not find Epo overexpression in CTNNB1/ARID1A mutated HCCs. However, the frequent hypoxia found in cancers rendered this observation not so surprising. This has been added as a supplemental figure (Figure 1—figure supplement 4) and in the text (subsection “Emergence of peliosis-like regions in the liver of [Apc-Arid1a]<sup>ko-focal</sup> mice”) and commented in the Discussion.</p><disp-quote content-type="editor-comment"><p>5) A statement regarding the cause of death in APC/Arid1 animals should be provided to support the authors claim that this is secondary to peliosis. This is not normally itself a fatal disorder, so why do the authors propose it is in this model? Similarly, is there correlation between the ultrasound findings and endpoint liver examination at post mortem?</p></disp-quote><p>To clarify this issue, we have added in Figure 1D a picture of a necropsy from a Apc/Arid 13-month old mouse whose entire liver was diseased with a dramatic erythrocytosis and no healthy area in its liver. This is representative of the 3 mice necropsied before dying, as they were reaching the endpoints: “At necropsy of dying mice, the whole liver was diseased, appearing dark red, filled with blood, with large necrotic areas, and no remaining healthy zones (Figure 1D, inset)”.</p><disp-quote content-type="editor-comment"><p>6) In line with general recommendations in mouse work it would be important to show that the key findings are present in both male and female model systems.</p></disp-quote><p>We agree with this comment. We did all the analyses in males because the initial question was to analyze liver carcinogenesis for which an important delay in females is described. We tried to generate new female mice with the different genotypes. We got no enough female mice with the 4 genotypes expected in March. Unfortunately, we could not continue the breedings due to the COVID19 crisis as the access to the animal facility has been severely restricted.</p><disp-quote content-type="editor-comment"><p>7) Additional replicates are necessary to show absence of effects of HIF targets. There do appear to be differences in at least some of these and it is likely that n=4 will be insufficient to demonstrate equivalence.</p></disp-quote><p>We agree with this comment and have expanded this analysis to n=8 (n=7 for Arid ko livers). There are some differences in the expression of Eno2, Car9 and Rab42 mRNA expressions, which were seen in Apcko and Apc/Aridko livers (Figure 7—figure supplement 1D-E). This underlines an overexpression of some HIF targets after β-catenin activation, and does not emphasize that Apc/Arid-ko livers are specifically HIF-activated. This is written in the text: “A small subset of Hif1α/Hif2α targets was slightly overexpressed in both Apc<sup>ko</sup> and Apc-Arid1a<sup>ko</sup> livers, such as Eno2, Car9 and Rab42, confirming that β-catenin and HIF signaling share some transcriptional targets (Figure 7—figure supplement 1D,E) ( Benhamouche et al., 2006).”</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>The manuscript of Riou et al. has been substantially modified and reorganised. The authors have performed the majority of the essential revisions, in particular the RNAscope analyses of EPO expression in the wild-type and mutant livers and kidneys. The only experiment that could not be performed was the analyses of the phenotype of the female mice that is likely to take a much longer time due to the COVID crisis that restricted access and breeding in the animal facility.</p><p>While the manuscript is very much improved, several issues still require attention and should be addressed before final acceptance.</p><p>1) In the rebuttal letter and in the revised text, the authors describe the EPO expression seen by RNAscope experiments as “bursty” or “stochastic”. While this may be the case, it is not fully justified, nor necessary to explain the phenotype to describe EPO expression in this way. The text should be modified.</p></disp-quote><p>We agree that our interpretation of RNAscope experiments was hypothetic. We have suppressed these words, and have only discussed the interest of single-RNA <italic>in situ</italic> hybridization approach to better describe gene expression in the liver, as it was done by Itzkovitz’ lab.</p><disp-quote content-type="editor-comment"><p>2) The ATAC-qPCR experiments did not reveal increased chromatin accessibility upon Arid1a inactivation, in fact, chromatin accessibility appeared to decrease compared to Apc inactivation alone. It appears that only a single primer set was used that overlaps with the TCF binding site. From this limited analysis, it is difficult to assess exact nucleosome positioning and how it may be affected by Arid1a loss. It would have been more appropriate to test several amplicons spanning the enhancer. This would have perhaps better revealed how Arid1a loss affects nucleosome positioning and accessibility.</p></disp-quote><p>We limited the chromatin accessibility analysis due to the difficulty to design accurate PCR primers in the region of the enhancer. For this revision, we finally designed three additional primer pairs which work for qPCR (added in the key resources table), but we could not technically try amplicons in the flanking regions, nor get an amplicon specific for the Hnf4/Wnt responsive element (see Figure 8—figure supplement 2A). We revealed an increased chromatin accessibility when the amplicon is centered on the Hnf4/Wnt responsive element. These data are added as Figure 8—figure supplement 2 and commented in the legend.</p><disp-quote content-type="editor-comment"><p>3) Last but not least, the quality of the English in the revised version is very poor leading to lack of precision and making the text difficult to follow. A thorough revision of the text by a native speaker is essential.</p></disp-quote><p>The text of the Results and the Discussion has been thoroughly revised by a professional scientific proofreader and editor.</p></body></sub-article></article>